

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/47, C07D 215/38, 215/227	A1	(11) International Publication Number: WO 99/09983 (43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17508		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 24 August 1998 (24.08.98)		
(30) Priority Data: 60/058,014 28 August 1997 (28.08.97) US		
(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; 5 Research Parkway, Wallingford, CT 06492-7660 (US).		
(72) Inventors: HEWAWASAM, Piyasena; 31 Brookview Lane, Middletown, CT 06457 (US). STARRETT, John, E., Jr.; 23 Hawks Nest Circle, Middletown, CT 06457 (US). SWARTZ, Stephen, G.; 162 Willow Lane, Warrington, PA 18976 (US).		Published <i>With international search report.</i>
(74) Agent: ALGIERI, Aldo, A.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660 (US).		

(54) Title: 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS



(57) Abstract

The present invention provides novel 4-aryl-3-aminoquinolin-2-one derivatives having general formula (I), wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined herein, or a non-toxic pharmaceutically acceptable salt thereof which are modulators of the large conductance calcium-activated K⁺ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**4-ARYL-3-AMINOQUINOLINE-2-ONE
5 DERIVATIVES AS POTASSIUM
CHANNEL MODULATORS**

10

FIELD OF THE INVENTION

The present invention is directed to novel 4-aryl-3-aminoquinolin-2-one derivatives which are modulators of the large-conductance calcium-activated potassium (BK) channels and, therefore, useful in the protection 15 of neuronal cells and diseases arising from dysfunction of cellular membrane polarization and conductance. The present invention also provides a method of treatment with the novel substituted quinolin-2-one derivatives and to pharmaceutical compositions thereof.

20

BACKGROUND OF THE INVENTION

Potassium channels play a key role in regulation of cell membrane potential and modulation of cell excitability. Potassium channels are 25 largely regulated by voltage, cell metabolism, calcium and receptor mediated processes. [Cook, N.S., Trends in Pharmacol. Sciences (1988), 9, 21; and Quast, U., et al, Trends in Pharmacol. Sciences (1989), 10, 431]. Calcium-activated potassium (K_{Ca}) channels are a diverse group of ion channels that share a dependence on intracellular calcium ions for 30 activity. The activity of K_{Ca} channels is regulated by intracellular $[Ca^{2+}]$,

membrane potential and phosphorylation. On the basis of their single-channel conductances in symmetrical K⁺ solutions, K_{Ca} channels are divided into three subclasses: large conductance (BK) > 150 pS; intermediate conductance 50-150 pS; small conductance < 50 pS. Large-
5 conductance calcium-activated potassium (Maxi-K or BK) channels are present in many excitable cells including neurons, cardiac cells and various types of smooth muscle cells. [Singer, J. et al., Pflugers Archiv. (1987) 408, 98; Baro, I., et al., Pflugers Archiv. (1989) 414 (Suppl. 1), S168; and Ahmed, F. et al., Br. J. Pharmacol. (1984) 83, 227].

10

Potassium ions play a dominant role in controlling the resting membrane potential in most excitable cells and maintain the transmembrane voltage near the K⁺ equilibrium potential (E_K) of about -90 mV. It has been shown that opening of potassium channels shift the cell
15 membrane potential towards the equilibrium potassium membrane potential (E_K), resulting in hyperpolarization of the cell. [Cook, N.S., Trends in Pharmacol. Sciences (1988), 9, 21]. Hyperpolarized cells show a reduced response to potentially damaging depolarizing stimuli. BK channels which are regulated by both voltage and intracellular Ca²⁺ act to
20 limit depolarization and calcium entry and may be particularly effective in blocking damaging stimuli. Therefore cell hyperpolarization via opening of BK channels may result in protection of neuronal cells.

A range of synthetic and naturally occurring compounds with BK
25 opening activity have been reported. The avena pyrone extracted from avena sativa-common oats has been identified as a BK channel opener using lipid bi-layer technique [International Patent application WO 93/08800, published May 13, 1993]. 6-Bromo-8-(methylamino)imidazo[1,2-a]pyrazine-2-carbonitrile (SCA-40) has been described as a
30 BK channel opener with very limited electrophysiological experiments

[Laurent, F. *et al.*, *Br. J. Pharmacol.* (1993) 108, 622-626]. The flavanoid, Phloretin has been found to increase the open probability of Ca²⁺-activated potassium channels in myelinated nerve fibers of *Xenopus laevis* using outside-out patches [Koh, D-S., *et al.*, *Neuroscience Lett.* 5 (1994) 165, 167-170].

In European patent application EP-477,819 published January 4, 1992 and corresponding U.S. Patent No. 5,200,422, issued April 6, 1993 to Olesen, *et al.*, a number of benzimidazole derivatives 10 were disclosed as openers of BK channels by using single-channel and whole-cell patch-clamp experiments in aortic smooth muscle cells. Further work was reported by Olesen, *et al* in *European J. Pharmacol.*, 251, 53-59 (1994).

15 A number of substituted oxindoles have been disclosed as openers of BK channels by P. Hewawasam, *et al*, in U.S. Patent No. 5,565,483, issued October 15, 1996.

E.S. Hamanaka in U.S. Patent No. 5,565,472, issued October 15, 20 1996, discloses a number of 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives which are inhibitors of acyl coenzyme A; cholesterol acyltransferase and are useful as hypolipidemic and antiatherosclerosis agents.

25 A. Walser, *et al*, *J. Org. Chem.*, 38, 449-456 (1973) disclose a limited number of 3-hydroxyquinolinones as by-products formed during the opening of the epoxide intermediate.

Y.S. Mohammed, *et al*, *Pharmazie*, 40, 312-314 (1985) discloses a 30 series of 4-substituted-3-hydroxy-2-quinolones as analogues of the

natural product viridicatin. The Merck Index, 11th Edition, 1575 (1989) briefly summarizes the references to the antibiotic substance, viridicatin.


- M.S. Masoud, et al, in Spectroscopy Letters, 21 (6), 369-383
 5 (1988) describe the spectral properties of several 2-quinolones as liquids and in Synth. React. Inorg. Met.-Org. Chem., 17, (8 & 9), 881-899 (1987) describe the equilibria and stability of the 2-quinolones in metallic complexes.
 10 It is the object of the present invention to provide novel compounds that will modulate potassium channels, in particular, large-conductance calcium-activated potassium (BK) channels which will be useful in reducing neuronal damage.

15

SUMMARY OF THE INVENTION

The present invention provides novel 4-aryl-3-aminoquinolin-2-one derivatives having the general formula

20




- wherein R, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined below, or a non-toxic pharmaceutically acceptable salt thereof which are openers of the large conductance calcium-activated K⁺ channels also known as Maxi-K or BK channels. The present invention also provides pharmaceutical compositions comprising said quinolin-2-one derivatives and to the method of treatment of disorders sensitive to potassium channel opening

activity such as ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction and urinary incontinence.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel 4-aryl-3-aminoquinolin-2-one derivatives which are potent openers of the high conductance, calcium-
10 activated K⁺-channels (BK channel) and which have the formula
10 activated K⁺-channels (BK channel) and which have the formula



wherein

- 15 R and R¹ each are independently hydrogen or methyl;
R², R³
and R⁴ each are independently hydrogen, halogen, nitro or
trifluoromethyl;
- 20 R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl,
trifluoromethylsulfonyl, naphthylsulfonyl, C₁₋₄ alkylcarbonyl,
diphenylphosphinyl, cyclohexylmethyl, pyridylmethyl,
furanylmethyl, furanyl-2-propenyl, imidazolylmethyl,
thienylmethyl, 1-methyl pyrrolylmethyl, unsubstituted or
substituted phenyl, phenylmethyl, phenylsulfonyl,
25 phenylcarbonyl, phenylalkylcarbonyl or phenylglyoxyloyl,
wherein said phenyl substituent is selected from the group

consisting of one or two fluoro, hydroxy, trifluoromethyl, amino, methoxy, methylthio and nitro; and

R⁶ hydrogen, bromo, chloro or nitro;
or a nontoxic pharmaceutically acceptable salt thereof.

5

The present invention also provides a method for the treatment or alleviation of disorders associated with BK channels, especially ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction and
10 urinary incontinence which comprises administering together with a conventional adjuvant, carrier or diluent a therapeutically effective amount of a compound of formula I or a nontoxic pharmaceutically acceptable salt thereof.

15 The term "nontoxic pharmaceutically acceptable salt" as used herein and in the claims is intended to include nontoxic base addition salts with inorganic bases. Suitable inorganic bases such as alkali and alkaline earth metal bases include metallic cations such as sodium, potassium, magnesium, calcium and the like.

20

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms including hydrated forms such as monohydrate, dihydrate, hemihydrate, trihydrate, tetrahydrate and the like. The products may be true solvates, while in other cases, the
25 products may merely retain adventitious solvent or be a mixture of solvate plus some adventitious solvent. It should be appreciated by those skilled in the art that solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

30

In the method of the present invention, the term "therapeutically effective amount" means the total amount of each active component of

the method that is sufficient to show a meaningful patient benefit, i.e., healing of acute conditions characterized by openers of large conductance calcium-activated K⁺ channels or increase in the rate of healing of such conditions. When applied to an individual active 5 ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously. The terms "treat, treating, treatment" as used herein and in the claims means preventing or 10 ameliorating diseases, tissue damage and/or symptoms associated with dysfunction of cellular membrane polarization and conductance.

Preferred compounds for use in the method of this invention include the compounds of Formula I listed below:

15 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl) quinolin-2(1H)-one;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-7-(trifluoromethyl) quinolin-2(1H)-one;

20 4-(5-Chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl) quinolin-2(1H)-one;

25 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-7-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;

30 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]methanesulfonamide;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl] phenylsulfonamide;

5 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-dichloroquinolin-2(1H)-one;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]aminocarboxylic acid, phenylmethyl ester;

10 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-nitroquinolin-2(1H)-one;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-7-nitroquinolin-2(1H)-one;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-

15 3-yl]diphenylphosphinamid;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,6-dichloroquinolin-2(1H)-one;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-

20 3-yl]-4-hydroxybenzenesulfonamide;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl) quinolin-2(1H)-one;

25 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-bis (trifluoromethyl)quinolin-2(1H)-one;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloroquinolin-2(1H)-one;

- 9 -

- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-7-(trifluoromethyl) quinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-5-(trifluoromethyl) quinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-iodoquinolin-2(1H)-one;
- 4-(5-Chloro-2-hydroxyphenyl)-3-[(4-hydroxyphenyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-hydroxyphenyl)-3-[(3,5-dihydroxyphenyl)-amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(3,5-dihydroxyphenyl)-amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(4-hydroxyphenyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-(trifluoromethyl) benzenesulfonamide;
- N-[4-(5-Chloro-2-hydroxyphenyl)-1-methyl-2-oxo-6-(trifluoro-methyl)-1H-quinolin-3-yl]-4-nitrobenzenesulfonamide;
- 3-Amino-4-(4-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one;
- 3-Amino-4-(5-bromo-2-hydroxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one;

- 10 -

- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-nitrobenzene-sulfonamide;
- 5 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-(4-fluorobenzene) sulfonamide;
- 3-Amino-4-(5-chloro-2-hydroxy-phenyl)-1-methyl-6-(trifluoro-methyl) quinolin-2(1H)-one;
- 10 3-Amino-4-(2-hydroxy-5-nitro-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one;
- 3-Amino-4-(3-chloro-4-hydroxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one
- 15 4-(5-Chloro-2-methoxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(4-pyridylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 20 4-(5-Chloro-2-methoxyphenyl)-3-[(phenylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(2-furanyl methyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 25 4-(5-Chloro-2-methoxyphenyl)-3-[(2-imidazolylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- (5-Chloro-2-methoxyphenyl)-3-[(2-imidazolylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 30

- 4-(5-Chloro-2-methoxyphenyl)-3-[(3-thienylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(1-methyl pyrrolylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[[[4-fluoro phenyl)methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 10 4-(5-Chloro-2-methoxyphenyl)-3-[(3-pyridylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(2-furanylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 15 4-(5-Chloro-2-methoxyphenyl)-3-[[[2-furanyl)-2-propenyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[[[4-(thiomethyl)phenyl]-methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 20 4-(5-Chloro-2-methoxyphenyl)-3-[(cyclohexylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one; and
- 25 4-(5-Chloro-2-methoxyphenyl)-3-[[[4-(methoxy)phenyl]-methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one.

The compounds of Formula I may be prepared by various procedures such as those illustrated herein in the examples, in the
30 Reaction Schemes and variations thereof which would be evident to those skilled in the art.

3-Aminoquinolin-2(1H)-ones

3-Aminoquinolin-2(1H)-one derivatives were prepared as outlined in Reaction Schemes 1 and 2. The starting 2-aminobenzophenones precursors were prepared by a variety of methods as depicted in Reaction Scheme 1. Reaction Scheme 2 represents the general route used for conversion of 2-aminobenzophenones to 3-aminoquinolin-2(1H)-ones. Further functionalization of the 3-amino moiety of the 3-aminoquinolin-2(1H)-ones were carried out as outlined in Reaction Schemes 3, 4 and 5.


10 The N-benzylation of the 3-amino moiety was carried out as depicted in Scheme 6 while N-alkylation of the 3-amino moiety was carried out by the general reaction depicted in Scheme 9. N-Aryl-3-aminoquinolinones were prepared as outlined in Reaction Schemes 6, 7 and 8.

15 REACTION SCHEME 1

Scheme 1.1

Method A: Directed Lithiation of Protected Anilines

20




$R^7 = CO_2^{'Bu}, COtBu$

Directed lithiation of a variety of protected anilines were employed for the preparation of requisite 2-aminobenzophenone precursors (4). The protocol utilizes the reaction of an *ortho*-lithiated, protected aniline derivative (1) with an aryl ester (2) to furnish a benzophenone derivative

(3). It is well established that when the amino group of an aniline is suitably protected it can direct metalation to the *ortho* position. Thus, N-Boc- and N-pivaloylanilines were widely used to prepare *ortho*-substituted aniline derivatives *via* the corresponding dianion species. The pattern of substitution of the 2-aminobenzophenones produced by this method is dependent upon the regiospecificity of the directed metalation.

Scheme 1.2


10 Method B: Addition of aryl Grignard reagents to benzoxazinones



15 The benzoxazinones (6) were generated by reaction of anthranilic acids (5) with excess acetic anhydride at reflux. Addition of (5-chloro-2-methoxyphenyl)magnesium bromide R⁶ = Cl to a THF solution of the benzoxazinone 6 provided the desired N-acetyl-2-aminobenzophenone derivatives. In general, when the substituents on the benzoxazinone nucleus are non-reactive towards the aryl Grignard reagent, N-acetyl-2-aminobenzophenones can be prepared in quite good yield. Deacetylation with 3N HCl in refluxing ethanol provided the desired 2-aminobenzophenones (4a).

Scheme 1.3


Method C: Oxidative ring opening of 3-aryl-3-hydroxyindolones



The 3-aryl-3-hydroxyindolones (9) were generated by addition of an aryl Grignard reagent (7) to isatins (8). It has been reported that oxidative ring opening of the 3-aryl-3-hydroxyindolone nucleus with either 10 basic hydrogen peroxide or basic potassium ferricyanide generates 2-aminobenzophenones. Attempted oxidative ring opening of 3-aryl-3-hydroxyindolones under basic conditions using either hydrogen peroxide or *tert*-butylhydroperoxide were not successful. Upon treatment of 3-aryl-3-hydroxyindolones (9) with K₃Fe(CN)₆ in 30% aqueous KOH followed by 15 heating on a steam bath for about 20-30 min quite readily opened the indolone nucleus to provide the desired 2-aminobenzophenones 4a.

Scheme 1.4


20 Method D: Curtius rearrangement of benzophenone-2-carboxylic acids



Curtius rearrangement of benzophenone-2-carboxylic acid (**11**) followed by hydrolysis of the intermediate isocyanate was used to generate 2-aminobenzophenones (**4b**). The requisite benzophenone-2-carboxylic acids (**11**) were prepared by addition of an aryl Grignard reagent (**7**) to a symmetrically substituted phthalic anhydride derivatives (**10**). The monoaddition of the aryl Grignard reagent can be accomplished by either carrying out the reaction at low temperature or complexing with CuI·SMe₂ complex. Curtius rearrangement of **11** using DPPA/Et₃N in refluxing toluene followed by hydrolysis of the intermediate isocyanate gave the desired 2-aminobenzophenones **4b**.

General method for the preparation of 3-aminoquinolone-2(1H)-one


As illustrated in Reaction Scheme 2, acylation of 2-aminobenzophenones (**4**) with haloacetyl halide in the presence of anhydrous pyridine gave the corresponding N-(haloacetyl) aminobenzophenones **12**. When a solution of N-(haloacetyl) aminobenzophenone in anhydrous pyridine was heated to reflux for 15-30 min, initially formed α -pyridinium acetanilide salt undergoes cyclization followed by dehydration to afford the 3-pyridinium halide salts (**13**). Upon dilution of the reaction mixture with anhydrous benzene the pyridinium salts were precipitated out and were isolated by filtration. Hydrazinolysis of pyridinium salts **13** in 85% hydrazine hydrate-ethanol (6:1) at reflux for 1-2 hr provided the corresponding 3-aminoquinolones **14**. The 3-aminoquinolones **14** were isolated by pouring the reaction mixture into cold water and then extracting with ether. The majority of crude 3-aminoquinolones are essentially pure and were used without further purification. Finally, demethylation of the methyl ether moiety with BBr₃ in methylene chloride afforded the desired phenols **15**.

REACTION SCHEME 2

5


Functionalization of the 3-amino group of 3-aminoquinolin-2(1H)-ones

- Selective monosulfonylation or acylation of the amino group of 16
 10 was not possible even with limited amounts of the corresponding reagents. Instead, as illustrated in Reaction Scheme 3, either persulfonylation or peracylation of 3-aminoquinolone 16 followed by treatment with aqueous NaOH in THF afforded the desired monosulfonated or monoacylated products 17a-d. Finally,
 15 demethylation of the methyl ether moiety of 17a-d with BBr_3 in methylene chloride afforded the desired phenols 18a-d.

REACTION SCHEME 3**B Conditions**


a) SO_2CF_3	1. $(\text{CF}_3\text{SO}_2)_2\text{O}$ / pyridine, r.t.	2. 3N NaOH, THF
b) SO_2Me	1. MeSO_2Cl / pyridine, heat	2. 3N NaOH, THF
c) SO_2Ar	1. ArSO_2Cl / pyridine, heat	2. 3N NaOH, THF
d) COMe(Ar)	1. Ac_2O or ArCOCl /pyridine, heat	2. 3N NaOH, THF

5 The benzyl amide analog **20** was prepared by peracylation of **19** with phenylacetyl chloride followed by selective deacetylation with 3N NaOH in MeOH-THF. The phenyl glyoxyamide analog **22** also prepared similar manner as shown in Reaction Scheme 4. The benzyl carbamate **21** was prepared by reacting **19** with excess CBz-Cl and triethylamine in
10 refluxing dichloroethane followed by treatment with 3N NaOH in methanol.

REACTION SCHEME 4

5 In Reaction Scheme 5, reaction of 16 with excess diphenyl phosphinyl chloride and triethylamine in refluxing DCE followed by treatment of the crude product with 3N NaOH in MeOH-THF gave the corresponding phosphinamide. Demethylation of the methyl ether intermediate with BBr_3 gave the desired phosphinamide 23.


REACTION SCHEME 5



5 N-benzylation of 3-amino moiety of 3-aminoquinolin-2(1H)-ones

As illustrated in Reaction Scheme 6, upon reaction of **19** with an aromatic aldehyde in refluxing toluene with removal of water formed the cyclic acetaminal intermediate **24**. After removal of the toluene the crude **24** was reduced directly with NaBH₄ in methylene chloride to provide the desired benzylamines **25**.

REACTION SCHEME 6




Preparation of N-Aryl-3-aminoquinolin-2(1H)-ones

Acylation of **4c** with bromoacetyl bromide gave the
 20 bromoacetanilide **26**, as shown in Reaction Scheme 7. Reaction of **26** with the sodium salt of N-Boc aniline in THF gave **27**. After addition of another equivalent of NaH, the reaction mixture was allowed to warm to

room temperature and maintained overnight. Under these conditions the intermediate **27** was cyclized and dehydrated to the desired quinolone. Upon treatment of the reaction mixture with 1N HCl, the Boc group was deprotected to afford the quinolone **28**, wherein R⁸ = hydroxyl, methoxy or 5 amino.


REACTION SCHEME 7



10

Another approach to synthesize the N-arylated 3-aminoquinolones involved direct N-arylation of the 3-amino moiety with triaryl bismuth as shown in Scheme 8.

REACTION SCHEME 8




5


N-Alkylation of 3-aminoquinolin-2(1H)-ones

As illustrated in Reaction Scheme 9, reaction of the 3-amino moiety of **16** with a solution of the desired aldehyde and titanium isopropoxide in THF gave an intermediate which was reduced with an excess of sodium borohydride to yield the corresponding alkylated amine **30**, wherein R⁹ represents optionally substituted phenyl, pyridyl, furanyl, imidazolyl, pyrrolyl, thienyl or cyclohexyl.

15 REACTION SCHEME 9



In a preferred embodiment of the invention the compounds of



- wherein R and R¹ each are independently hydrogen or methyl; R², R³ and R⁴ each are independently hydrogen, chloro, nitro or trifluoromethyl; R⁵ is
- 5 hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl, trifluoromethylsulfonyl, cyclohexylmethyl, pyridylmethyl, furanylmethyl, furanyl-2-propenyl, imidazolylmethyl, thienylmethyl, 1-methyl pyrrolylmethyl, unsubstituted or substituted phenyl, phenylmethyl, phenylcarbonyl or phenylsulfonyl wherein said phenyl substituent is selected from one or two fluoro,
- 10 hydroxy, trifluoromethyl, methoxy, methylthio and nitro; and R⁶ is chloro; or a nontoxic pharmaceutically acceptable salt thereof.

In another preferred embodiment of the invention the compound of Formula II include those wherein R is hydrogen; R¹ is hydrogen or methyl;

15 R², R³ and R⁴ each are independently chloro, nitro or trifluoromethyl; R⁵ is hydrogen, methyl, C₁₋₄ alkylsulfonyl, trifluoromethylsulfonyl, unsubstituted or substituted phenyl, phenylmethyl, phenylmethyl, phenylcarbonyl or phenylsulfonyl wherein said phenyl substituent is selected from one or two fluoro, hydroxy, trifluoromethyl, methoxy, phenylthio and nitro; and R⁶ is chloro; or a nontoxic pharmaceutically acceptable salt thereof.

In another aspect, this invention provides a method for the treatment of or protection from disorders which are mediated by opening

25 of the large conductance calcium-activated K⁺ channels (BK channels) in a mammal in need thereof, which comprises administering to said

mammal a therapeutically effective amount of a compound of Formula I or a nontoxic pharmaceutically acceptable salt thereof. Preferably, the compounds of Formula I are useful in the treatment of ischemia, convulsions, asthma, irritable bowel syndrome, migraine, traumatic brain

5 injury, male erectile dysfunction, and urinary incontinence and other disorders sensitive to BK channel activating activity.

In still another aspect, this invention provides pharmaceutical compositions comprising at least one compound of Formula I in

10 combination with a pharmaceutical adjuvant, carrier or diluent.

Biological Activity

Potassium (K^+) channels are structurally and functionally diverse

15 families of K^+ -selective channel proteins which are ubiquitous in cells, indicating their central importance in regulating a number of key cell functions [Rudy, B., *Neuroscience*, 25: 729-749 (1988)]. While widely distributed as a class, K^+ channels are differentially distributed as individual members of this class or as families. [Gehlert, D.R., *et al.*,

20 *Neuroscience*, 52: 191-205 (1993)]. In general, activation of K^+ channels in cells, and particularly in excitable cells such as neurons and muscle cells, leads to hyperpolarization of the cell membrane, or in the case of depolarized cells, to repolarization. In addition to acting as an endogenous membrane voltage clamp, K^+ channels can respond to

25 important cellular events such as changes in the intracellular concentration of ATP or the intracellular concentration of calcium (Ca^{2+}). The central role of K^+ channels in regulating numerous cell functions makes them particularly important targets for therapeutic development.

[Cook, N.S., Potassium channels: Structure, classification, function and

30 therapeutic potential. Ellis Horwood, Chichester (1990)]. One class of

K⁺ channels, the large-conductance Ca²⁺-activated K⁺ channels (Maxi-K or BK channels), is regulated by transmembrane voltage, intracellular Ca²⁺, and a variety of other factors such as the phosphorylation state of the channel protein. [Latorre, R., et al., Ann. Rev. Physiol., 51: 385-399 5 (1989)]. The large, single channel-conductance (generally > 150 pS) and high degree of specificity for K⁺ of BK channels indicates that small numbers of channels could profoundly affect membrane conductance and cell excitability. Additionally, the increase in open probability with increasing intracellular Ca²⁺ indicates involvement of BK channels in the 10 modulation of Ca²⁺-dependent phenomena such as secretion and muscular contraction. [Asano, M., et al., J. Pharmacol. Exp. Ther., 267: 1277-1285 (1993)].

Openers of BK channels exert their cellular effects by increasing 15 the open probability of these channels [McKay, M.C., et al., J. Neurophysiol., 71: 1873-1882 (1994); and Olesen, S.-P., Exp. Opin. Invest. Drugs, 3: 1181-1188 (1994)]. This increase in the opening of individual BK channels collectively results in the hyperpolarization of cell membranes, particularly in depolarized cells, produced by significant 20 increases in whole-cell BK-mediated conductance.

The ability of compounds described in the present invention to open BK channels and increase whole-cell outward (K⁺) BK-mediated currents was assessed under voltage-clamp conditions by determining 25 their ability to increase cloned mammalian (mSlo or hSlo) BK - mediated outward current heterologously expressed in Xenopus oocytes [Butler, A., et al., Science, 261: 221-224 (1993); and Dworetzky, S.I., et al., Mol. Brain Res., 27: 189-193 (1994)]. The two BK constructs employed represent nearly structurally identical homologous proteins, and have 30 proven to be pharmacologically identical in our tests. To isolate BK

current from native (background, non-BK) current, the specific and potent BK channel-blocking toxin iberiotoxin (IBTX) [Galvez, A., et al., *J. Biol. Chem.*, 265: 11083-11090 (1990)] was employed at a supramaximal concentration (50 nM). The relative contribution of BK channels current to 5 total outward current was determined by subtraction of the current remaining in the presence of IBTX (non-BK current) from the current profiles obtained in all other experimental conditions (control, drug, and wash). It was determined that at the tested concentration the compounds profiled did not effect non-BK native currents in the oocytes. All 10 compounds were tested in at least 5 oocytes and are reported at the single concentration of 20 μ M; the effect of the selected compounds of Formula I on BK current was expressed as the percent of control IBTX-sensitive current and is listed in Table I. Recordings were accomplished using standard two-electrode voltage clamp techniques [Stuhmer, W., et 15 al., *Methods in Enzymology*, Vol. 207: 319-339 (1992)]; voltage-clamp protocols consisted of 500-750 ms duration step depolarizations from a holding potential of -60 mV to +140 mV in 20 mV steps. The experimental media (modified Barth's solution) consisted of (in mM): NaCl (88), NaHCO₃ (2.4), KCl (1.0), HEPES (10), MgSO₄ (0.82), Ca(NO₃)₂ (0.33), 20 CaCl₂ (0.41); pH 7.5.

TABLE 1**Effect of Selected Compounds on BK Channels**

Ex. No	BK Current*
2	++
5	++
10	+
14	+
17	++
19	++
29	+
32	+
43	+
44	+
64	++
66	++
68	+
71	+

* at 20μM expressed as percent increase over BK current in controls

5 + = 100 - 150%

++ = > 150%

To determine the ability of these compounds to reduce cell loss resulting from neuronal ischemia, a standard rodent model of permanent focal ischemia, involving occlusion of the middle cerebral artery in the spontaneously hypertensive rat (MCAO model) was employed [Tamura, A., *et al.*, Journal of Cerebral Blood Flow and Metabolism, Volume 1, 53-60, (1981)].

Selected compounds have been evaluated in the focal stroke model involving permanent middle cerebral artery occlusion (MCAO) in the spontaneously hypertensive rat. This procedure results in a reliably large neocortical infarct volume that is measured by means of vital dye exclusion in serial slices through the brain 24 hours after MCAO. In the present test, compounds were administered using an intravenous route of administration at 30 minutes after occlusion. For example, in this model, the compound of Example 2 reduced the cortical infarct volume by about 14% when administered (0.001 mg/kg) as a single bolus 30 minutes after middle cerebral artery occlusion as compared to vehicle-treated (2% DMSO, 98% propylene glycol) control.

The results of the above biological tests demonstrates that the compounds of the instant invention are potent openers of the large-conductance calcium-activated K⁺ channels (Maxi-K or BK channels). Thus, the compounds of the present invention are useful for the treatment of human disorders arising from dysfunction of cellular membrane polarization and conductance and, preferably, are indicated for the treatment of ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction, and urinary incontinence and other disorders sensitive to BK channel activating activity.

In another embodiment, this invention includes pharmaceutical compositions comprising at least one compound of Formula I in combination with a pharmaceutical adjuvant, carrier or diluent.

In still another embodiment, this invention relates to a method of treatment or prevention of disorders responsive to opening of potassium channels in a mammal in need thereof, which comprises administering to

said mammal a therapeutically effective amount of a compound of Formula I or a nontoxic pharmaceutically acceptable salt thereof.

- For therapeutic use, the pharmacologically active compounds of
- 5 Formula I will normally be administered as a pharmaceutical composition comprising as the (or an) essential active ingredient at least one such compound in association with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional
- 10 techniques.

The pharmaceutical compositions include suitable dosage forms for oral, parenteral (including subcutaneous, intramuscular, intradermal and intravenous) bronchial or nasal administration. Thus, if a solid carrier

15 is used, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge. The solid carrier may contain conventional excipients such as binding agents, fillers, tableting lubricants, disintegrants, wetting agents and the like. The tablet may, if desired, be film coated by conventional techniques. If a liquid

20 carrier is employed, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, sterile vehicle for injection, an aqueous or non-aqueous liquid suspension, or may be a dry product for reconstitution with water or other suitable vehicle before use. Liquid preparations may contain conventional additives such as suspending agents, emulsifying

25 agents, wetting agents, non-aqueous vehicle (including edible oils), preservatives, as well as flavoring and/or coloring agents. For parenteral administration, a vehicle normally will comprise sterile water, at least in large part, although saline solutions, glucose solutions and like may be utilized. Injectable suspensions also may be used, in which case

30 conventional suspending agents may be employed. Conventional preservatives, buffering agents and the like also may be added to the

parenteral dosage forms. Particularly useful is the administration of a compound of Formula I directly in parenteral formulations. The pharmaceutical compositions are prepared by conventional techniques appropriate to the desired preparation containing appropriate amounts of 5 the active ingredient, that is, the compound of Formula I according to the invention. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 17th edition, 1985.

The dosage of the compounds of Formula I to achieve a 10 therapeutic effect will depend not only on such factors as the age, weight and sex of the patient and mode of administration, but also on the degree of potassium channel activating activity desired and the potency of the particular compound being utilized for the particular disorder of disease concerned. It is also contemplated that the treatment and dosage of the 15 particular compound may be administered in unit dosage form and that the unit dosage form would be adjusted accordingly by one skilled in the art to reflect the relative level of activity. The decision as to the particular dosage to be employed (and the number of times to be administered per day) is within the discretion of the physician, and may be varied by 20 titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect.

A suitable dose of a compound of Formula I or pharmaceutical composition thereof for a mammal, including man, suffering from, or likely 25 to suffer from any condition as described herein is an amount of active ingredient from about 0.01 µg/kg to 10 mg/kg body weight. For parenteral administration, the dose may be in the range of 0.1 µg/kg to 1 mg/kg body weight for intravenous administration. The active ingredient will preferably be administered in equal doses from one to four times a day. However, 30 usually a small dosage is administered, and the dosage is gradually

increased until the optimal dosage for the host under treatment is determined.

- However, it will be understood that the amount of the compound
5 actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

10

The following examples are given by way of illustration and are not to be construed as limiting the invention in any way inasmuch as many variations of the invention are possible within the spirit of the invention.

15

DESCRIPTION OF SPECIFIC EMBODIMENTS

- In the following examples, all temperatures are given in degrees Centigrade. Melting points were recorded on a Gallenkamp capillary
20 melting point apparatus are uncorrected. Proton magnetic resonance (¹H NMR) spectra were recorded on a Bruker AC 300 spectrometer. All spectra were determined in the solvents indicated and chemical shifts are reported in δ units downfield from the internal standard tetramethylsilane (TMS) and interproton coupling constants are reported in Hertz (Hz).
25 Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; dd, doublet of doublet; bd, broad doublet; dt, doublet of triplet; bs, broad singlet; dq, doublet of quartet. Infrared (IR) spectra using potassium bromide (KBr) were determined on a Perkin Elmer 781 spectrometer from 4000 cm⁻¹ to 400
30 cm⁻¹, calibrated to 1601 cm⁻¹ absorption of a polystyrene film and reported in reciprocal centimeters (cm⁻¹). Low resolution mass spectra

(MS) and the apparent molecular weight (MH^+) or ($M-H^-$) was determined on a Finnigan TSQ 7000. The element analyses are reported as percent by weight.

- 5 The following procedures Nos.1-6 illustrate representative general procedures for the preparation of intermediates and methods for the preparation of products according to this invention. It should also be evident to those skilled in the art that appropriate substitution of both the materials and methods disclosed herein will produce the examples
10 illustrated below and those encompassed by the scope of this invention.

Procedure 1

15 General procedure for the metalation of (trifluoromethyl) anilines

Tert-BuLi (2.2-2.4 eqt.) was added to a cold (-78 °C) stirred solution of N-Boc or N-pivaloyl protected aniline (1.0 eqt.) in anhydrous THF (~ 1 molar) under nitrogen. The resultant mixture was warmed to 20 -45°-40 °C and maintained for 2-3 hrs. The resultant suspension or solution of the dianion was cooled to -78 °C and neat dry methyl 5-chloro-2-methoxybenzoate (1.1 eqt.) was added rapidly. The resultant solution was warmed to -40 °C and maintained for 1 hr. The reaction was diluted with ether and quenched with 1N HCl and then allowed to warm to room 25 temperature. The organic layer was separated, washed with water, brine and then dried (Na_2SO_4). The crude isolated product was purified by either recrystallization or trituration or silica gel flash column chromatography.

Procedure 2**General procedure for N-acylation and N-alkoxycarbonylation of 3-aminoquinolinones**

5 Neat acyl chloride or acyl anhydride or alkyl chloroformate (3-4 eqt.) was added to a cold (0-5 °C) solution of 3-aminoquinolin-2(1H)-one (1 eqt.) and anhydrous pyridine (5 eqt.) in anhydrous CH₂Cl₂. The reaction mixture was allowed to warm to ambient temperature and then
10 heated to reflux for several hours until the reaction is complete. The reaction was cooled in an ice bath and quenched with 1N NaOH solution for 0.5 hr and then acidified with 1N HCl. The product was extracted with CH₂Cl₂ and washed with brine and then dried (MgSO₄). The crude product was purified by either recrystallization or trituration or flash
15 column chromatography.

Procedure 3**20 General procedure for N-sulfonylation of 3-aminoquinolinones**

20 Neat alkyl or aryl sulfonyl chloride (3-4 eqt.) was added to a cold (0-5 °C) solution of 3-aminoquinolin-2(1H)-one (1 eqt.) and anhydrous pyridine (5 eqt.) in anhydrous THF. The reaction mixture was allowed to
25 warm to ambient temperature and the progress of the reaction was followed by TLC. The reaction was cooled in an ice bath and quenched with 3N NaOH solution for 0.5-1 hr and then acidified with 1N HCl. The product sulfonamide was extracted with ether, washed with brine and then dried (Na₂SO₄). The crude sulfonamide was purified by either
30 recrystallization or trituration or flash column chromatography.

Procedure 4**General procedure for the synthesis of N-arylated 3-aminoquinolinones**

5

Sodium hydride (2.2 eqt.) was added to a cold (0 °C) solution of the N-boc-aniline (2 eqt.) in anhydrous THF. The mixture was stirred for 30 min and then a THF solution of N-[2-[(5-chloro-2-methoxyphenyl) carbonyl]-4-(trifluoromethyl)phenyl]bromoacetamide (1 eqt.) was added.

10 The mixture was allowed to warm to room temperature and stirred for 24-48 hrs. The reaction was acidified with 1N HCl and then stirred for 30 min. After neutralization with satd. NaHCO₃ the product was extracted with ether, washed with brine and then dried (Na₂SO₄). The crude product was purified by flash column chromatography.

15

Procedure 5**General procedure for N-benzylation of 3-aminoquinolinones**

20

A stirred mixture of 3-amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-1*H*-quinolin-2-one and excess benzaldehyde in anhydrous toluene was heated to reflux for 3-4 hrs. Then toluene was rotary evaporated and the resultant residue was dissolved in anhydrous CH₂Cl₂ and then treated with excess sodium triacetoxyborohydride. The mixture stirred overnight and carefully quenched with 1N HCl and then neutralized with satd. NaHCO₃. The organic layer was separated, washed with brine and then dried (MgSO₄). The crude product was purified by flash chromatography.

30

Procedure 6General procedure for N-substituted methylation of 3-aminoquinolinones

5

A solution of aldehyde (2 eq., 2.72 mmol) and titanium isopropoxide (0.81 mL, 2.72 mmol) was stirred for one hour under nitrogen. A solution of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one (500 mg. 1.36 mmol) and dry THF

10 (4 mL) was then added and stirred and monitored by thin layer chromatography. If the reaction showed less than 50% of the starting material remaining by thin layer chromatography, it was taken on to the reduction procedure. Otherwise the reaction was heated to 65°C for 24 hours before proceeding.

15

The reaction mixture was diluted with absolute ethanol and heated to reflux. An excess of sodium borohydride (6 eq.) was added and refluxed for three hours. After cooling, the reaction was quenched with 1N hydrochloric acid and the resulting solids were collected by filtration.

20 The solids were washed several times with methylene chloride and combined with the filtrate. The filtrate was concentrated and the resulting material chromatographed on silica gel affording the desired product.

EXAMPLE 13-Amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl) quinolin-2(1H)-one

5

STEP A. N-[2-[(5-Chloro-2-methoxyphenyl) carbonyl]-4-(trifluoromethyl) phenyl]aminocarboxylic acid, 1,1-dimethylethyl ester

10 A stirred neat mixture of 4-aminobenzotrifluoride (35 g, 0.218 mol) and (Boc)₂O (52.4g, 0.24 mol) was heated at 80°C for 2-3 hours until CO₂ evolution ceased. The mixture was allowed to cool and the tBuOH was rotary evaporated. The resultant white solid was recrystallized from hexanes/ether to provide white needles (50.6 g, 89%) of
15 N-(tert-butoxycarbonyl)-4-aminobenzotrifluoride.

Tert-BuLi (130 mL, 0.22 mol, 1.7M in cyclohexane) was added over 20 minutes to a cold (-78 °C) stirred solution of N-Boc-4-aminobenzotrifluoride (26.2 g, 0.1 mol) in dry THF (130 mL) under argon.

20 The resultant yellow partial solution was warmed to -45°-40 °C and maintained for 2 hrs. The resultant thick yellow slurry of the dianion was cooled to -78 °C and neat dry methyl 5-chloro-2-methoxybenzoate (22.1 g, 0.11 mol) was added rapidly. The resultant yellow-brown solution was warmed to -40 °C and maintained for 1 hr. The reaction was diluted with
25 ether (200 mL) and quenched with 1N HCl (250 mL) and then allowed to warm to room temperature. The organic layer was separated, washed with water, brine and then dried (Na₂SO₄). Evaporation of solvents gave a light-yellow solid (49.9 g) which was triturated with ether to afford 31.9 g of pure desired titled compound: mp 148-150 °C; IR (KBr, cm⁻¹) 3280,
30 1725, 1640, 1530, 1320, 1250, 1150; ¹H NMR (300 MHz, DMSO-d₆) δ 1.41 (9 H, s), 3.58 (3 H, s), 7.19 (1 H, d, J = 8.9 Hz), 7.49 (1 H, d, J = 2.7

- 36 -

Hz), 7.58 (1 H, d, J = 2.6 Hz), 7.60 (1 H, dd, J = 8.9 and 2.7 Hz), 7.93 (1 H, dd, J = 8.7 and 1.9 Hz), 8.12 (1 H, s), 8.15 (1 H, m), 10.35 (1 H, s); MS m/e 430 (MH⁺).

5 Anal. calcd. for C₂₀H₁₉ClF₃NO₄: C, 55.88; H, 4.45; N, 3.25.
Found: C, 55.51; H, 4.38; N, 3.26.

STEP B. 1-[2-Amino-5-(trifluoromethyl)phenyl]-1'-(5-chloro-2-methoxyphenyl) methanone

10 To a stirred solution of N-[2-[(5-chloro-2-methoxyphenyl) carbonyl]-4-(trifluoromethyl)phenyl]aminocarboxylic acid, 1,1-dimethylethyl ester (19 g, 0.044 mol) in ethanol (300 mL), 3N HCl was added. The resultant suspension was heated to reflux for 3 hrs. The progress of the hydrolysis
15 was monitored by TLC. The reaction mixture was cooled and poured into cold water (500 mL). The product was extracted with ether (2X200 mL) and the combined ether extracts were washed with water, brine and then dried (Na₂SO₄). Evaporation of the ether gave a golden yellow viscous oil which upon standing overnight solidified to afford a beige solid (14.6 g,
20 100%): mp 90-92 °C; IR (KBr, cm⁻¹) 3340, 3470, 1640, 1320, 1240, 1150, 1025; ¹H NMR (300 MHz, DMSO-d₆) δ 3.68 (3 H, s), 6.97 (1 H, d, J = 8.8 Hz), 7.19 (1 H, d, J = 8.9 Hz), 7.26 (1 H, d, J = 1.1 Hz), 7.36 (1 H, d, J = 2.7 Hz), 7.53 (2 H, m), 7.92 (2 H, brd s); MS m/e 330 (MH⁺).
25 Anal. calcd. for C₁₅H₁₁ClF₃NO₂: C, 54.64; H, 3.36; N, 4.25.
Found: C, 54.65; H, 3.37; N, 4.16.

STEP C. N-[2-[(5-Chloro-2-methoxyphenyl)carbonyl]-4-(trifluoromethyl)phenyl]chloroacetamide

30

A solution of chloroacetyl chloride (5.1 mL, 0.053 mol) in anhydrous CH₂Cl₂ (20 mL) was added dropwise over 15-20 min to a stirred cold (0 °C) solution of 1-[2-amino-5-(trifluoromethyl)phenyl]-1'-(5-chloro-2-methoxyphenyl)methanone (14.6 g, 0.044 mol) and 5 anhydrous pyridine (4.3 mL, 0.053 mol) in CH₂Cl₂ (80 mL). The resultant mixture was allowed to warm to room temperature and maintained for 1 hr. The reaction was acidified with 1N HCl (50 mL). The organic layer was separated and washed consecutively with satd. NaHCO₃, water, brine and then dried (MgSO₄). Evaporation of the CH₂Cl₂ gave a beige 10 solid (18.7 g). The crude product was triturated with ether to afford an off-white solid (16.23 g, 91%): mp 136-137 °C; IR (KBr, cm⁻¹) 1694, 1644, 1522, 1314, 1124; ¹H NMR (300 MHz, CDCl₃) δ 3.67 (3 H, s), 4.23 (2 H, s), 6.93 (1 H, d, J = 8.8 Hz), 7.38 (1 H, d, J = 2.6 Hz), 7.48 (1 H, dd, J = 8.8 and 2.6 Hz), 7.69 (1 H, s), 7.79 (1 H, d, J = 8.8 Hz), 8.87 (1 H, d, J = 8.8 Hz), 12.30 (1 H, s); MS m/e 404 (M-H)⁻. 15

STEP D. 1-[4-(5-Chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]pyridinium, chloride

20 A mechanically stirred solution of N-[2-[(5-chloro-2-methoxyphenyl)carbonyl]-4-(trifluoromethyl) phenyl]chloroacetamide (12.2 g, 0.03 mol) in anhydrous pyridine (150 mL) was heated to reflux for 20-25 min. The resultant suspension of the pyridinium salt was allowed to cool and then diluted with benzene (100 mL). The pyridinium salt was 25 filtered, washed with benzene and then dried in vacuo to afford the desired titled compound (13.75 g, 98%): mp 325-330 °C (dec.); IR (KBr, cm⁻¹) 1678, 1322, 1270, 1118; ¹H NMR (300 MHz, DMSO-d₆) δ 3.59 (3 H, s), 7.09 (1 H, d, J = 9.0 Hz), 7.38 (1 H, s), 7.44 (1 H, d, J = 2.6 Hz), 7.52 (1 H, dd, J = 8.9 and 2.6 Hz), 7.83 (1 H, d, J = 8.7 Hz), 8.11 (1 H, dd,

J = 8.7 and 1.8 Hz), 8.19-8.27 (2 H, m), 8.70-8.75 (1 H, m), 9.05-9.07 (2 H, m), 13.54 (1 H, brd s); MS m/e 431 (MH)⁺.

Anal. calcd. for C₂₂H₁₅Cl₂F₃N₂O₂•0.33H₂O: C, 55.84; H, 3.34; N, 5.92.
5 Found: C, 55.83; H, 3.33; N, 5.84.

STEP E. 3-Amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one

10 Hydrazine (25 mL, 85%w/w) was added to a stirred suspension of
1-[4-(5-chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-
3-yl]pyridinium, chloride (13.5 g, 0.029 mol) in ethanol (150 ml). The
resultant red-brown solution was heated to reflux for 1.5 hrs. The reaction
mixture was allowed to cool to room temperature and then poured into
15 cold water (300 mL). The precipitated product was extracted with ether
(2X200 mL). The combined ether extracts were washed wth water (200
mL), brine (100 mL) and then dried (Na₂SO₄). Evaporation of the ether
gave an off-white solid (10.80 g) which was triturated with ether/hexanes
to afford the desired titled compound (10.6 g, 99%): mp 246-248 °C
20 (dec.); IR (KBr, cm⁻¹) 3400, 1668, 1332, 1284, 1118; ¹H NMR (300 MHz,
DMSO-d₆) δ 3.66 (3 H, s), 5.24 (2 H, brd s), 6.87 (1 H, s), 7.22 (1 H, d, J =
2.6 Hz), 7.24 (1 H, d, J = 8.8 Hz), 7.40 (1 H, d, J = 8.5 Hz), 7.45 (1 H, d, J
= 8.5 Hz), 7.51 (1 H, dd, J = 8.8 and 2.6 Hz), 12.31 (1 H, brd s); MS m/e
369 (MH)⁺.

25

Anal. calcd. for C₁₇H₁₂ClF₃N₂O₂: C, 55.37; H, 3.28; N, 7.60.
Found: C, 55.26; H, 3.46; N, 7.53.

EXAMPLE 23-Amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl) quinolin-2(1H)-one

5

A boron tribromide solution in CH₂Cl₂ (1M, 12 mL 12 mmol) was added to a cold (-20 °C) stirred suspension of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)-2-(1H)-quinolone (1.47 g, 3 mmol) in anhydrous CH₂Cl₂ (20 mL) under nitrogen. The reaction flask was closed with a glass stopper and the mixture was stirred at room temperature for 6-8 hrs. The progress of the demethylation was monitored by TLC. The reaction was quenched with 1N NaOH (36 mL) and then the pH of the aqueous phase was adjusted to 7 with either satd. NaHCO₃ or 1N HCl. Since the product was not completely soluble in CH₂Cl₂, the CH₂Cl₂ layer was separated and rotary evaporated at room temperature. The organic residue was dissolved in EtOAc (50 mL) and combined with the aqueous layer in the separatory funnel. The product was completely extracted into the EtOAc and washed with water, brine and then dried (Na₂SO₄). Evaporation of the EtOAc gave a light-brown semi-solid (1.53 g) which was triturated with CH₂Cl₂ to afford the titled compound as a beige solid (1.38 g, 97%): mp 233-235 °C; IR (KBr, cm⁻¹) 3300, 1670, 1330, 1280, 1122; ¹H NMR (300 MHz, DMSO-d₆) δ 5.15 (2 H, brd s), 6.96 (1 H, s), 7.03 (1 H, d, J = 8.7 Hz), 7.14 (1 H, d, J = 2.6 Hz), 7.33 (1 H, dd, J = 8.7 and 2.6 Hz), 7.40 (1 H, d, J = 8.4 Hz), 7.46 (1 H, d, J = 8.6 Hz), 9.69 (1 H, s), 12.28 (1 H, s); MS m/e 355 (MH)⁺.

EXAMPLE 33-Amino-4-(5-chloro-2-methoxyphenyl)-7-(trifluoromethyl) quinolin-2(1H)-one

5

mp 245-248 °C (dec.); IR (KBr, cm⁻¹) 3368, 1664, 1316, 1234, 1120; ¹H NMR (300 MHz, CDCl₃) δ 3.56 (3 H, s), 4.39 (2 H, brd s), 6.89 (2 H, m), 7.07-7.09 (2 H, m), 7.26-7.29 (1 H, m), 7.43 (1 H, s), 12.04 (1 H, brd s); MS m/e 367 (M-H)⁺.

10

Anal. calcd. for C₁₇H₁₂ClF₃N₂O₂: C, 55.37; H, 3.28; N, 7.60.
Found: C, 55.32; H, 3.13; N, 7.77.

15

EXAMPLE 43-Amino-4-(5-chloro-2-hydroxyphenyl)-7-(trifluoromethyl) quinolin-2(1H)-one

20

mp 225-227 °C; IR (KBr, cm⁻¹) 3350, 1666, 1318, 1254, 1126; ¹H NMR (300 MHz, DMSO-d₆) δ 5.27 (2 H, brd s), 6.90 (1 H, d, J = 8.4 Hz), 7.02 (1 H, d, J = 8.7 Hz), 7.11 (1 H, d, J = 2.6 Hz), 7.27-7.34 (2 H, m), 7.54 (1 H, s), 9.64 (1 H, s), 12.20 (1 H, s); MS m/e 355 (MH)⁺.

25

EXAMPLE 5N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide

30

mp 268-270 °C; IR (KBr, cm⁻¹) 1118, 1206, 1280, 1322, 1650, 3180; ¹H NMR (300 MHz, DMSO-d₆) δ 7.00 (1 H, d, J = 8.7 Hz), 7.18 (1 H, d, J = 2.5 Hz), 7.31 (1 H, s), 7.38 (1 H, dd, J = 8.7 and 2.5 Hz), 7.55 (1 H, d, J = 8.6 Hz), 7.88 (1 H, d, J = 8.6 Hz), 10.09 (1 H, brd s), 12.63 (1 H, s); MS 5 m/e 487 (MH)⁺.

Anal. calcd. for C₁₇H₉ClF₆N₂O₄S: C, 41.95; H, 1.86; N, 5.75.

Found: C, 41.46; H, 1.95; N, 5.57.

10

EXAMPLE 6

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-7-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide

15

mp 267-270 °C; IR (KBr, cm⁻¹) 1134, 1220, 1328, 1644, 2500-3600; ¹H NMR (300 MHz, DMSO-d₆) δ 6.98 (1 H, d, J = 8.7 Hz), 7.15 (1 H, d, J = 2.6 Hz), 7.27 (1 H, d, J = 8.5 Hz), 7.36 (1 H, dd, J = 8.7 and 2.6 Hz), 7.45 (1 H, d, J = 8.6 Hz), 7.67 (1 H, s), 10.0 (1 H, brd s), 12.50 (1 H, s); MS 20 m/e 487 (MH)⁺.

Anal. calcd. for C₁₇H₉ClF₆N₂O₄S•0.5H₂O: C, 41.16; H, 2.04; N, 5.65.

Found: C, 41.15; H, 1.98; N, 5.61.

25

EXAMPLE 7

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]acetamide

30

mp 222-224 °C; IR (KBr, cm⁻¹) 1128, 1172, 1324, 1672, 2100-3600; ¹H NMR (300 MHz, DMSO-d₆) δ 6.98 (1 H, d, J = 8.7 Hz), 7.07 (1 H, d, J = 2.6 Hz), 7.24 (1 H, s), 7.34 (1 H, dd, J = 8.6 and 2.6 Hz), 7.51 (1 H, d, J = 8.6 Hz), 7.80 (1 H, d, J = 8.8 Hz), 9.10 (1 H, brd s), 10.0 (1 H, brd s), 12.4 5 (1 H, brd s); MS m/e 397 (MH)⁺.

EXAMPLE 8

10 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]methanesulfonamide

mp 263-265 °C; IR (KBr, cm⁻¹) 1140, 1322, 1662, 3400; ¹H NMR (300 MHz, DMSO-d₆) δ 7.00 (1 H, d, J = 8.7 Hz), 7.17 (1 H, d, J = 2.6 Hz), 7.21 15 (1 H, s), 7.37 (1 H, dd, J = 8.7 and 2.6 Hz), 7.53 (1 H, d, J = 8.6 Hz), 7.82 (1 H, d, J = 8.7 Hz), 8.78 (1 H, s), 9.99 (1 H, s), 12.51 (1 H, s); MS m/e 431 (M-H)⁻.

EXAMPLE 9

20

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl] phenylsulfonamide

mp 262-265 °C; IR (KBr, cm⁻¹) 1116, 1170, 1280, 1322, 1340, 1660, 25 3474; ¹H NMR (300 MHz, DMSO-d₆) δ 6.85 (1 H, d, J = 8.7 Hz), 7.08 (1 H, d, J = 2.6 Hz), 7.22 (2 H, m), 7.39 (2 H, m), 7.51 (2 H, m), 7.58 (2 H, m), 7.80 (1 H, d, J = 6.8 Hz), 9.2 (1 H, brd s), 9.9 (1 H, brd s), 12.38 (1 H, s); MS m/e 495 (MH)⁺.

30

EXAMPLE 10N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]benzamide

5

mp 309-311 °C (dec.); IR (KBr, cm⁻¹) 1122, 1270, 1322, 1504, 1654, 3192; ¹H NMR (300 MHz, DMSO-d₆) δ 6.96 (1 H, d, J = 8.7 Hz), 7.19 (1 H, d, J = 2.6 Hz), 7.27 (1 H, dd, J = 8.7 and 2.6 Hz), 7.32 (1 H, s), 7.43 (2 H, t, J = 7.7 Hz), 7.51 (1 H, d, J = 7.2 Hz), 7.56 (1 H, d, J = 8.4 Hz), 10 7.74 (2 H, d, J = 7.1 Hz), 7.85 (1 H, d, J = 8.7 Hz), 9.62 (1 H, s) 10.05 (1 H, s), 12.51 (1 H, s); MS m/e 459 (MH)⁺.

EXAMPLE 11

15

4-(5-Chloro-2-hydroxyphenyl)-3-(phenylmethyl)amino-6-(trifluoromethyl)quinolin-2(1H)-one

mp 215-217 °C; IR (KBr, cm⁻¹) 1118, 1330, 1646, 3300; ¹H NMR (300 MHz, CDCl₃-CD₃OD) δ 3.80 (1 H, d, J = 14.3 Hz), 3.93 (1 H, d, J = 14.3 Hz), 6.86 (1 H, d, J = 8.7 Hz), 6.92 (1 H, d, J = 2.6 Hz), 6.99 (1 H, s), 7.01 (1 H, d, J = 2.0 Hz), 7.11-7.28 (6 H, m), 7.36 (1 H, dd, J = 8.5 and 1.7 Hz); MS m/e 445 (MH)⁺.

EXAMPLE 123-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-dichloroquinolin-2(1H)-one

5

mp 275-277 °C; IR (KBr, cm⁻¹) 1668, 3400; ¹H NMR (300 MHz, DMSO-d₆) δ 5.00 (2 H, s), 6.87 (1 H, d, J = 8.7 Hz), 7.03 (1 H, d, J = 2.5 Hz), 7.12 (1 H, d, J = 2.0 Hz), 7.24 (1 H, dd, J = 8.6 and 2.5 Hz), 7.29 (1 H, d, J = 1.7 Hz), 9.55 (1 H, s), 12.28 (1 H, s); MS m/e 353 (M-H)⁻.

10

EXAMPLE 1315 3-Amino-4-(5-chloro-2-methoxyphenyl)quinolin-2(1H)-one

mp 248-250 °C; IR (KBr, cm⁻¹) 750, 1250, 1658, 3000; ¹H NMR (300 MHz, CDCl₃) δ 3.72 (3 H, s), 6.94 (1 H, d, J = 7.4 Hz), 7.02 (1 H, d, J = 8.9 Hz), 7.06 (1 H, t, J = 6.9 Hz), 7.23-7.27 (2 H, m), 7.30 (1 H, t, J = 7.4 Hz), 7.40 (1 H, dd, J = 8.8 and 2.6 Hz), 11.2 (1 H, brd s); MS m/e 301 (MH⁺).

EXAMPLE 14

25

3-Amino-4-(5-chloro-2-hydroxyphenyl)quinolin-2(1H)-one

mp 265-268 °C; IR (KBr, cm⁻¹) 748, 1656, 3300; ¹H NMR (300 MHz, DMSO-d₆) δ 4.82 (2 H, s), 6.75 (1 H, d, J = 7.8 Hz), 6.97 (1 H, t, J = 7.7 Hz), 7.01 (1 H, d, J = 8.7 Hz), 7.08 (1 H, d, J = 2.6 Hz), 7.15 (1 H, t, J =

7.1 Hz), 7.23 (1 H, d, J = 7.9 Hz), 7.30 (1 H, dd, J = 8.7 and 2.6 Hz), 9.62 (1 H, s), 11.93 (1 H, s); MS m/e 287 (MH⁺).

5

EXAMPLE 153-Amino-4-(2-hydroxyphenyl)quinolin-2(1H)-one

mp 235-237 °C; IR (KBr, cm⁻¹) 748, 1218, 1658, 3300; ¹H NMR (300 MHz, DMSO-d₆) δ 4.62 (2 H, s), 6.79 (1 H, d, J = 8.0 Hz), 6.91-6.98 (2 H, m), 7.01 (1 H, d, J = 8.2 Hz), 7.07 (1 H, d, J = 7.5 Hz), 7.15 (1 H, t, J = 7.0 Hz), 7.23-7.30 (2 H, m), 9.36 (1 H, s), 11.91 (1 H, s); MS m/e 253 (MH⁺).

Anal. calcd. for C₁₅H₁₂N₂O₂·0.22H₂O: C, 70.31; H, 4.89; N, 10.93.
15 Found: C, 70.30; H, 4.75; N, 10.88.

EXAMPLE 16

20 3-Amino-4-(5-chloro-2-methoxyphenyl)-5,7-dichloroquinolin-2(1H)-one

mp 284-287 °C; IR (KBr, cm⁻¹) 1244, 1666, 2100-3600; MS m/e 369 (MH⁺).

25

EXAMPLE 17

30 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]aminocarboxylic acid, phenylmethyl ester

- 46 -

mp 234-236 °C (dec.); IR (KBr, cm⁻¹) 698, 1130, 1324, 1498, 1652, 1690;
¹H NMR (300 MHz, DMSO-d₆) δ 4.96 (1 H, d, J = 13.0 Hz), 5.00 (1 H, d, J
= 13.0 Hz), 6.99 (1 H, d, J = 8.7 Hz), 7.12 (1 H, d, J = 2.6 Hz), 7.52 (1 H,
d, J = 8.6 Hz), 7.81 (1 H, d, J = 8.6 Hz), 8.67 (1 H, s), 9.97 (1 H, s), 12.45
5 (1 H, s); MS m/e 489 (MH⁺).

EXAMPLE 18

10 **3-Amino-4-(5-chloro-2-methoxyphenyl)-6-nitroquinolin-2(1H)-one**

mp 332-335 °C (dec.); IR (KBr, cm⁻¹) 1338, 1588, 1664; ¹H NMR (300
MHz, DMSO-d₆) δ 3.69 (3 H, s), 5.41 (2 H, s), 7.27 (1 H, d, J = 2.4 Hz),
7.30 (1 H, s), 7.41 (1 H, d, J = 8.9 Hz), 7.50 (1 H, d, J = 2.4 Hz), 7.56
15 (1 H, dd, J = 8.9 and 2.6 Hz), 8.02 (1 H, dd, J = 8.9 and 2.4 Hz), 12.56
(1 H, s); MS m/e 344 (M-H)⁻.

EXAMPLE 19

20

3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-nitroquinolin-2(1H)-one

mp 344-347 °C; IR (KBr, cm⁻¹) 1340, 1670, 3370; ¹H NMR (300 MHz,
DMSO-d₆) δ 5.33 (2 H, s), 7.07 (1 H, d, J = 8.7 Hz), 7.19 (1 H, d, J = 2.6
Hz), 7.38 (1 H, dd, J = 8.8 and 2.7 Hz), 7.43 (1 H, s), 7.58 (1 H, d, J = 2.4
Hz), 8.03 (1 H, dd, J = 8.9 and 2.5 Hz), 9.76 (1 H, s), 12.54 (1 H, s); MS
m/e 330 (M-H)⁻.

EXAMPLE 20**N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]phenylacetamide**

5

mp 278-281 °C (dec.); IR (KBr, cm⁻¹) 1122, 1322, 1656; ¹H NMR (300 MHz, DMSO-d₆) δ 3.46 (2 H, m), 6.95-7.00 (3 H, m), 7.05 (1 H, d, J = 2.6 Hz), 7.18-7.25 (4 H, m), 7.35 (1 H, dd, J = 8.7 and 2.7 Hz), 7.54 (1 H, d, J = 8.6 Hz), 7.82 (1 H, d, J = 8.8 Hz), 9.39 (1 H, s), 9.93 (1 H, s), 12.46 (1 H, s); MS m/e 471 (M-H)⁻.

EXAMPLE 21**15 4-(5-Chloro-2-methoxyphenyl)-3-(phenylamino)-6-(trifluoromethyl)quinolin-2(1H)-one**

A stirred suspension of 1 equivalent each of Example 1, triphenylbismuth, copper acetate and 2 eqts. of triethylamine in dichloroethane was sonicated for 1 hr and then stirred overnight at rt. The reaction mixture filtered through a pad of celite. The filtrate was concentrated and flash columned (silica gel/3% MeOH in methylene chloride) to afford 4-(5-chloro-2-methoxyphenyl)-3-(phenylamino)-6-(trifluoromethyl)quinolin-2(1H)-one: mp 235-240 °C (dec.); IR (KBr, cm⁻¹) 1124, 1274, 1328, 1658; ¹H NMR (300 MHz, CDCl₃) δ 3.67 (3 H, s), 6.62 (1 H, d, J = 8.8 Hz), 6.75 (1 H, d, J = 8.0 Hz), 6.85 (2 H, m), 6.98 (2 H, m), 7.08 (1 H, m), 7.27 (3 H, m), 7.50 (1 H, d, J = 6.9 Hz), 11.31 (1 H, s); MS m/e 443 (M-H)⁻.

EXAMPLE 22**N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]phenylglyoxyamide**

5

mp 255-260 °C (dec.); IR (KBr, cm⁻¹) 1132, 1322, 1670; ¹H NMR (300 MHz, DMSO-d₆) δ 7.06 (1 H, d, J = 8.5 Hz), 7.22 (1 H, s), 7.30 (1 H, m), 7.44-7.60 (5 H, m), 7.69-7.76 (2 H, m), 7.87 (1 H, d, J = 8.8 Hz); MS m/e 485 (M-H)⁻.

10

EXAMPLE 23**3-Amino-4-(5-chloro-2-hydroxyphenyl)-7-nitroquinolin-2(1H)-one**

15

mp 198-201 °C (dec.); IR (KBr, cm⁻¹) 1332, 1516, 1664, 3368; ¹H NMR (300 MHz, DMSO-d₆) δ 5.73 (2 H, s), 6.88 (1 H, d, J = 8.9 Hz), 7.03 (1 H, d, J = 8.7 Hz), 7.14 (1 H, d, J = 2.7 Hz), 7.35 (1 H, dd, J = 8.7 and 2.7 Hz), 7.84 (1 H, dd, J = 8.9 and 2.4 Hz), 8.13 (1 H, d, J = 2.4 Hz), 9.69 (1 H, s), 12.39 (1 H, s); MS m/e 330 (M-H)⁻.

EXAMPLE 24**25 3-Amino-4-(5-chloro-2-methoxyphenyl)-7-nitroquinolin-2(1H)-one**

mp 293-295 °C; IR (KBr, cm⁻¹) 1332, 1520, 1670; ¹H NMR (300 MHz, DMSO-d₆) δ 3.68 (3 H, s), 5.81 (2 H, s), 6.81 (1 H, d, J = 8.9 Hz), 7.22 (1 H, d, J = 2.7 Hz), 7.24 (1 H, d, J = 8.8 Hz), 7.53 (1 H, dd, J = 8.8 and

2.7 Hz), 7.82 (1 H, dd, J = 8.9 and 2.4 Hz), 8.13 (1 H, d, J = 2.4 Hz), 12.41 (1 H, brd s); MS m/e 344 (M-H)⁻.

5

EXAMPLE 25N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]diphenylphosphinamide

- 10 A stirred suspension of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)-1H-quinolin-2-one (184 mg, 0.5 mmol), triethylamine (0.21 mL, 1.5 mmol) and diphenylphosphinyl chloride (355 mg, 1.5 mmol) in dichloroethane (2 mL) was heated to reflux for 4-5 hrs. The reaction was quenched with 1N HCl and extracted with CH₂Cl₂. After evaporation
15 of CH₂Cl₂ the resultant residue was dissolved in THF and treated with 3N NaOH for 1-2 hrs. The mixture was acidified with 1N HCl and then extracted with ether, washed with brine and then dried (Na₂SO₄). The crude product was triturated with CH₂Cl₂ to afford pure desired phosphinamide. Demethylation of the methyl ether moiety with BBr₃ gave
20 the desired phenolic phosphinamide: mp 257-260 °C; IR (KBr, cm⁻¹) 692, 728, 1126, 1190, 1274, 1664; ¹H NMR (300 MHz, DMSO-d₆) δ 6.82 (1 H, d, J = 7.5 Hz), 6.87 (1 H, d, J = 8.7 Hz), 7.08 (1 H, s), 7.14 (1 H, d, J = 2.6 Hz), 7.20 (1 H, dd, J = 8.7 and 2.6 Hz), 7.37-7.50 (7 H,m), 7.60-7.72 (4 H, m), 9.95 (1 H, s), 12.42 (1 H, s); MS m/e 553 (M-H)⁻.

25

EXAMPLE 26**3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,6-dichloroquinolin-2(1H)-****5 one**

mp 263-265 °C; IR (KBr, cm^{-1}) 1266, 1662, 3382; ^1H NMR (300 MHz, DMSO- d_6) δ 5.06 (2 H, s), 6.90 (1 H, d, J = 8.7 Hz), 7.06 (1 H, d, J = 2.6 Hz), 7.25-7.29 (2 H, m), 7.39 (1 H, d, J = 8.7 Hz), 9.57 (1 H, s), 12.31
10 (1 H, s); MS m/e 353 ($M-\text{H}$) $^-$.

EXAMPLE 27**15 3-Amino-4-(5-chloro-2-methoxyphenyl)-5,6-dichloroquinolin-2(1H)-**
one

mp 275-278 °C (dec.); IR (KBr, cm^{-1}) 1240, 1660, 3392; ^1H NMR (300 MHz, DMSO- d_6) δ 3.69 (3 H, s), 5.12 (2 H, s), 7.11 (1 H, d, J = 8.9 Hz),
20 7.14 (1 H, d, J = 2.7 Hz), 7.28 (1 H, d, J = 8.8 Hz), 7.39 (1 H, d, J = 8.7 Hz), 7.45 (1 H, dd, J = 8.8 and 2.7 Hz), 12.34 (1 H, s); MS m/e 367 ($M-\text{H}$) $^-$.

EXAMPLE 28

- 5 **N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-methoxybenzamide**
- mp 285-287 °C; IR (KBr, cm⁻¹) 1076, 1120, 1173, 1259, 1323, 1656, 2800-3400; ¹H NMR (300 MHz, DMSO-d₆) δ 3.79 (3 H, s), 6.95-6.98 (3 H, m), 7.19 (1 H, m), 7.28 (1 H, dd, J = 8.7 and 2.7 Hz), 7.32 (1 H, s), 7.56 (1 H, d, J = 8.6 Hz), 7.76 (2 H, d, J = 7.4 Hz), 7.84 (1 H, d, J = 8.7 Hz), 9.45 (1 H, s), 10.03 (1 H, s), 12.49 (1 H, s); MS m/e 489 (MH)⁺.

EXAMPLE 29

- 15
- 15 **N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-hydroxybenzamide**
- mp 286-289 °C (dec.); IR (KBr, cm⁻¹) 1119, 1323, 1654, 3194; ¹H NMR (300 MHz, DMSO-d₆) δ 6.76 (2 H, d, J = 8.7 Hz), 6.96 (1 H, d, J = 8.7 Hz), 7.18 (1 H, d, J = 2.6 Hz), 7.27 (1 H, dd, J = 8.7 and 2.7 Hz), 7.31 (1 H, s), 7.55 (1 H, d, J = 8.6 Hz), 7.65 (2 H, d, J = 8.7 Hz), 7.84 (1 H, d, J = 8.7 Hz), 9.31 (1 H, s), 10.04 (1 H, s), 12.48 (1 H, s); MS m/e 473 (M-H)⁻.

25

EXAMPLE 30

- 25 **4-(5-Chloro-2-hydroxyphenyl)-3-[[[4-methoxyphenyl] methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one**

30

mp 103-106 °C; IR (KBr, cm⁻¹) 1118, 1329, 1657, 3200; MS m/e 473 (M-H)⁻.

5

EXAMPLE 31

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-hydroxybenzenesulfonamide

10 mp 180-185 °C (dec.); IR (KBr, cm⁻¹) 1147, 1322, 1662, 3233; ¹H NMR (300 MHz, DMSO-d₆) δ 6.71 (2 H, d, J = 8.8 Hz), 6.91 (1 H, d, J = 8.7 Hz), 7.10 (1 H, d, J = 2.6 Hz), 7.24 (1 H, s), 7.27 (1 H, dd, J = 8.7 and 2.6 Hz), 7.42 (2 H, d, J = 8.8 Hz), 7.47 (1 H, d, J = 8.6 Hz), 7.80 (1 H, d, J = 8.6 Hz), 8.80 (1 H, brd s), 9.92 (1 H, brd s), 10.25 (1 H, brd s), 12.38 (1 H, s); MS m/e 511 (MH⁺).

EXAMPLE 32

20 **N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-[4-methoxyphenyl]acetamide**

mp 172-175 °C; IR (KBr, cm⁻¹) 1076, 1120, 1169, 1249, 1322, 1659, 2100-3200; ¹H NMR (300 MHz, DMSO-d₆) δ 3.42 (2 H, m), 3.72 (3 H, s), 6.75 (2 H, d, J = 8.7 Hz), 6.91 (2 H, d, J = 8.6 Hz), 6.96 (1 H, d, J = 8.7 Hz), 7.02 (1 H, d, J = 2.6 Hz), 7.24 (1 H, s), 7.34 (1 H, dd, J = 8.7 and 2.6 Hz), 7.54 (1 H, d, J = 8.6 Hz), 7.82 (1 H, dd, J = 8.7 and 1.7 Hz), 9.30 (1 H, brd s), 9.91 (1 H, brd s), 12.44 (1 H, brd s); MS m/e 503 (MH⁺).

EXAMPLE 33N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]- (4-hydroxyphenyl)acetamide

5

mp 218-221 °C; IR (KBr, cm⁻¹) 1120, 1170, 1323, 1661, 2800-3300; ¹H NMR (300 MHz, DMSO-d₆) δ 3.4 (2 H, m), 6.58 (2 H, d, J = 8.4 Hz), 6.77 (2 H, d, J = 8.4 Hz), 6.97 (1 H, d, J = 8.7 Hz), 7.06 (1 H, d, J = 2.6 Hz), 7.25 (1 H, s), 7.34 (1 H, dd, J = 8.7 and 2.6 Hz), 7.54 (1 H, d, J = 8.6 Hz), 10 7.82 (1 H, d, J = 8.7 Hz), 9.17 (1 H, s), 9.25 (1 H, s), 9.92 (1 H, s), 12.44 (1 H, s); MS m/e 487 (M-H)⁻.

EXAMPLE 343-Amino-4-(5-chloro-2-methoxyphenyl)-8-(trifluoromethyl) quinolin-15 2(1H)-one

mp 265-266 °C; IR (KBr, cm⁻¹) 1670, 1300, 1126; ¹H NMR (300 MHz, CDCl₃) δ 7.57 (1 H, d, J = 7.8 Hz), 7.49 (1 H, d, J = 7.8 Hz), 7.39-7.35 (dd, 1 H, J = 2.7 Hz and J = 9.0 Hz), 7.27 (1 H, t, J = 7.2 Hz), 7.11(s, 1 H), 20 6.94 (d, 1 H, J = 8.7 Hz); MS m/e 368 (MH⁺).

Anal. calcd. for C₁₇H₁₂ClF₃N₂O₂: C, 55.37; H, 3.28; N, 7.60.

Found: C, 55.40; H, 3.43; N, 7.50.

25

EXAMPLE 353-Amino-4-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl) quinolin-2(1H)-one

30

mp 267-268 °C; IR (KBr, cm⁻¹) 1666, 1338, 1136; ¹H NMR (300 MHz, DMSO-d₆) δ 7.59 (1 H, d, J = 7.9 Hz), 7.50 (1 H, d, J = 6.8 Hz), 7.35-7.30 (m, 1 H), 7.25 (1 H, dd, J = 2.6 and 8.7 Hz), 6.97 (s, 1 H), 6.92 (d, 1 H, J = 8.7 Hz); MS m/e 354 (MH⁺).

5

Anal. calcd. for C₁₆H₁₀ClF₃N₂O₂: C, 51.51; H, 3.21; N, 7.51.

Found: C, 51.88; H, 2.72; N, 7.48.

10

EXAMPLE 36

3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-bis-(trifluoromethyl)quinolin-2(1H)-one

15 mp 230-233 °C; IR (KBr, cm⁻¹) 1674, 1278, 1134; ¹H NMR (300 MHz, DMSO-d₆) δ 7.88 (1 H, s), 7.67 (1 H, s), 7.29-7.25 (m, 1 H), 7.03 (1 H, s), 6.97 (s, 1 H), 6.92 (d, 1 H, J = 8.7 Hz); MS m/e 422 (MH⁺).

20

Anal. calcd. for C₁₇H₉ClF₆N₂O₂: C, 48.30; H, 2.15; N, 6.63.

Found: C, 48.54; H, 2.57; N, 6.11.

EXAMPLE 37

25 **3-Amino-4-(5-chloro-2-methoxyphenyl)-5,7-bis-(trifluoromethyl)quinolin-2(1H)-one**

mp 265-267 °C; IR (KBr, cm⁻¹) 1670, 1278, 1130; MS m/e 436 (MH⁺).

30

EXAMPLE 38**3-Amino-4-(5-chloro-2-methoxyphenyl)-6-chloro-(trifluoromethyl)quinolin-2(1H)-one**

5

mp >300 °C; IR (KBr, cm⁻¹) 3368, 1658, 1246; ¹H NMR (300 MHz, CDCl₃) δ 7.47-7.43 (1 H, dd, J = 2.7 and 9.0 Hz), 7.23-7.19 (2 H, dd, J = 2.7 and 9.0 Hz), 7.13 (d, 1 H, J = 8.4 Hz), 7.04 (1 H, d, J = 8.7 Hz), 6.89 (d, 1 H, J = 2.1 Hz); MS m/e 334 (MH⁺).

10

Anal. calcd. for C₁₆H₁₂Cl₂N₂O₂: C, 57.33; H, 3.61; N, 8.36.

Found: C, 57.22; H, 3.79; N, 8.22.

15

EXAMPLE 39**3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloroquinolin-2(1H)-one**

mp 184-185 °C; IR (KBr, cm⁻¹) 3500-2700, 1652, 1250; ¹H NMR (300 MHz, DMSO-d₆) δ 7.34 (1 H, dd, J = 8.7 and 2.7 Hz), 7.26 (1 H, d, J = 8.4 Hz), 7.19 (1 H, dd, J = 8.7 and 2.4 Hz), 7.13 (1 H, d, J = 2.7 Hz), 7.04 (1 H, d, J = 8.7 Hz), 6.65 (1 H, d, J = 2.4 Hz); MS m/e 320 (MH⁺).

25

Anal. calcd. for C₁₅H₁₀Cl₂N₂O₂•0.5H₂O: C, 54.52; H, 3.33; N, 8.48.

Found: C, 54.92; H, 3.44; N, 8.29.

EXAMPLE 40

30 **3-Amino-4-(5-chloro-2-methoxyphenyl)-6,7-dichloroquinolin-2(1H)-one**

mp >300 °C; IR (KBr, cm⁻¹) 1672, 1248; ¹H NMR (300 MHz, CDCl₃) δ 7.55-7.51 (1 H, dd, J = 2.7 and 9.0 Hz), 7.43 (1 H, s), 7.25 (d, 1 H, J = 9.0 Hz), 7.22 (1 H, d, J = 2.7 Hz), 6.71(1 H, s); MS m/e 368 (MH⁺).

5

Anal. calcd. for C₁₆H₁₁Cl₃N₂O₂: C, 51.99; H, 3.00; N, 7.58.

Found: C, 52.15; H, 3.20; N, 7.59.

10

EXAMPLE 41

3-Amino-4-(5-chloro-2-hydroxyphenyl)-6,7-dichloroquinolin-2(1H)-one

15 mp 305-307 °C; IR (KBr, cm⁻¹) 3300, 1668, 1264; ¹H NMR (300 MHz, DMSO-d₆) δ 7.35 (1 H, s), 7.22 (1 H, s), 7.12 (1 H, d, J = 2.7 Hz), 7.06 (1 H, t, J = 2.7 Hz), 6.97 (1 H, s); MS m/e 354 (MH⁺).

Anal. calcd. for C₁₅H₉Cl₃N₂O₂: C, 50.66; H, 2.55; N, 7.88.
20 Found: C, 50.82; H, 2.51; N, 7.63.

EXAMPLE 42

25 **3-Amino-4-(5-chloro-2-methoxyphenyl)-6-chloro-7-(trifluoromethyl)quinolin-2(1H)-one**

mp 252-253 °C; IR (KBr, cm⁻¹) 1672, 1278, 1314, 1130; ¹H NMR (300 MHz, CDCl₃) δ 7.68(1 H, s), 7.56-7.52 (1 H, dd, J = 2.7 and 8.7 Hz), 7.26 (d, 1 H, J = 6.9 Hz), 7.24 (1 H, s), 6.74(1 H, s), 3.70(3 H, s); MS m/e 402 (MH⁺).

Anal. calcd. for $C_{17}H_9ClF_6N_2O_2$: C, 50.64; H, 2.75; N, 6.95.
Found: C, 50.59; H, 3.02; N, 6.77.

5

EXAMPLE 43

3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-7-(trifluoromethyl)quinolin-2(1H)-one

10

mp 245-246 °C; IR (KBr, cm^{-1}) 1314, 1232, 1138; 1H NMR (300 MHz, DMSO-d₆) δ 7.68 (1 H, s), 7.35 (1 H, dd, J = 8.7 and 2.7 Hz), 7.24 (1 H, d, J = 2.7 Hz), 7.16 (1 H, d, J = 2.7 Hz), 7.04 (1 H, d, J = 8.7 Hz), 6.81(s, 1 H); MS m/e 388 (MH⁺).

15

Anal. calcd. for $C_{16}H_9Cl_2F_3N_2O_2$: C, 49.38; H, 2.33; N, 7.20.
Found: C, 49.49; H, 2.54; N, 6.91.

20

EXAMPLE 44

3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-5-(trifluoromethyl)quinolin-2(1H)-one

25

mp 139-140 °C; IR (KBr, cm^{-1}) 1668, 1334, 1138, 1134; 1H NMR (300 MHz, DMSO-d₆) δ 7.47-7.40 (2 H, dd, J= 12.0 Hz), 7.23 (1 H, d, J = 6.6 Hz), 6.95 (1 H, d, J = 8.7 Hz), 6.85 (1 H, s); MS m/e 388 (MH⁺).

30

Anal. calcd. for $C_{16}H_9Cl_2F_3N_2O_2$: C, 49.38; H, 2.33; N, 7.20.
Found: C, 49.65; H, 2.76; N, 6.58.

EXAMPLE 453-Amino-4-(5-chloro-2-methoxyphenyl)-6-chloro-5-(trifluoromethyl)quinolin-2(1H)-one

5

mp 228 °C; ^1H NMR (300 MHz, DMSO) δ 7.44-7.39(3 H, m), 7.14 (1 H, d, J = 8.7 Hz), 6.91 (d, 1 H, J = 2.7 Hz), 3.77(3 H, s); MS m/e 402 (MH^+).

Anal. calcd. for $\text{C}_{17}\text{H}_{11}\text{Cl}_2\text{F}_3\text{N}_2\text{O}_2$: C, 50.64; H, 2.75; N, 6.95.

10

Found: C, 51.00; H, 2.92; N, 6.82.

EXAMPLE 4615 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-iodoquinolin-2(1H)-one

mp 160-162 °C; IR (KBr, cm^{-1}) 1656, 1276; ^1H NMR (300 MHz, DMSO) δ 7.46-7.43 (1 H, dd, J = 1.8 and 8.4 Hz), 7.36-7.32 (1 H, dd, J = 2.7 and 8.7 Hz), 7.12 (d, 1 H, J = 2.7 Hz), 7.08-7.02 (3 H, m), 6.98 (d, 1 H, J = 1.8 Hz); MS m/e 412 (MH^+).

Anal. calcd. for $\text{C}_{15}\text{H}_{10}\text{ClN}_2\text{O}_2$: C, 43.66; H, 2.44; N, 6.79.

Found: C, 43.93; H, 2.55; N, 6.54.

25

EXAMPLE 47**4-(5-Chloro-2-methoxyphenyl)-3-[(4-methoxyphenyl)amino]-6-trifluoromethylquinolin-2(1H)-one**

5

mp 245-246 °C; ^1H NMR (300 MHz, DMSO) δ 7.59-7.46 (3 H, m), 7.21-7.18 (1 H, dd, J = 2.7 and 8.7 Hz), 7.02 (s, 1 H), 6.95(d, J = 2.7 Hz, 1 H), 6.86 (1 H, d, J = 8.7 Hz), 6.53-6.49(4 H, m), 3.64 (3 H, s), 3.62(s, 3 H); MS m/e 474 (MH^+).

10

EXAMPLE 48**4-(5-Chloro-2-hydroxyphenyl)-3-[(4-hydroxyphenyl)amino]-6-**15 **(trifluoromethyl)quinolin-2(1H)-one**

mp 145-165 °C; ^1H NMR (300 MHz, CD_3OD) δ 7.51-7.42 (2 H, m), 7.28 (1 H, s), 6.99-6.95 (dd, 1 H, J = 2.4 and 8.7 Hz), 6.82(d, 1 H, J = 2.4 Hz), 6.68-6.59 (3 H, m), 6.42-6.25(2 H, m) ; MS m/e 446 (MH^+).

20

Anal. calcd. for $\text{C}_{22}\text{H}_{14}\text{ClF}_3\text{N}_2\text{O}_3 \cdot 0.5\text{H}_2\text{O}$: C, 57.92; H, 3.29; N, 6.14.
Found: C, 57.56; H, 3.39; N, 6.06.

25

EXAMPLE 49**4-(5-Chloro-2-hydroxyphenyl)-3-[(3,5-dihydroxyphenyl)-amino]-6-(trifluoromethyl)quinolin-2(1H)-one**

30 mp 148-160 °C; ^1H NMR (300 MHz, CD_3OD) δ 7.58-7.48 (2 H, dd, J = 8.4 and 2.7 Hz), 7.41 (1 H, s), 7.08-7.04 (dd, 1 H, J= 2.7 and 8.7 Hz), (d, 1 H,

J = 2.7 Hz), 6.80 (1 H, d, J = 8.7 Hz), 5.77(2 H, s), 5.73(s, 1 H) ; MS m/e 462 (MH⁺).

EXAMPLE 50

5

4-(5-Chloro-2-methoxyphenyl)-3-[(3,5-dimethoxyphenyl)-amino]-6-(trifluoromethyl)quinolin-2(1H)-one

mp 253-254 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.84 (1 H, d, J = 2.7 Hz),
10 7.60 (1 H, d J = 2.4 Hz), 7.44-7.40 (m, 2H), 7.00 (1 H, d, J = 8.4 Hz), 7.02
(d, 1 H, J = 8.7 Hz), 6.54 (2 H, s), 6.41(t, 1 H, J = 2.4 Hz), 3.74(s, 6 H),
3.64(s, 3 H) ; MS m/e 548 (MH⁺).

15

EXAMPLE 51

4-(5-Chloro-2-methoxyphenyl)-3-[(3,5-dihydroxyphenyl)- amino]-6-(trifluoromethyl)quinolin-2(1H)-one

20 mp 155-165 °C; ¹H NMR (300 MHz, CD₃OD) δ 7.58-7.45 (2 H, dd, J = 8.4
and 3.0 Hz), 7.27 (1 H, s), 7.21 (d, 1 H, J = 2.7 Hz), 7.0 (1 H, s), 6.94 (d,
1 H, J = 9.0 Hz), 5.73(2 H, s), 3.76(s, 6 H) ; MS m/e 476 (MH⁺).

Anal. calcd. for C₂₃H₁₆ClF₃N₂O₄: C, 56.81; H, 3.50; N, 5.76.
25 Found: C, 56.49; H, 3.58; N, 5.36.

EXAMPLE 524-(5-Chloro-2-methoxyphenyl)-3-[(4-hydroxyphenyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

5

mp 165-175 °C; ^1H NMR (300 MHz, CD₃OD) δ 7.51-7.42 (2 H, dd, J = 2.1 and 7.6 Hz), 7.14 (2 H, m), 6.94(s, 1 H), 6.75 (d, 1 H, J = 8.7 Hz), 6.62(d, 2 H, J = 8.1 Hz), 6.39 (2 H, d, J = 8.4 Hz), 3.75 (3 H, s); MS m/e 460 (MH⁺).

10

Anal. calcd. for C₂₃H₁₆ClF₃N₂O₃: C, 58.74; H, 3.62; N, 5.96.

Found: C, 58.09; H, 3.68; N, 5.61.

<u>Ex. No.</u>	<u>Compound</u>	<u>MP °C</u>	<u>Empirical Formula</u>	<u>Elemental Analysis Calc'd.</u>	<u>Elemental Analysis Found</u>
5.3	N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-(trifluoromethyl) benzenesulfonamide	215-225 (dec.)	C ₂₃ H ₁₃ ClF ₆ N ₂ O ₄ S•0.1H ₂ O	C, 45.55 H, 2.60 N, 4.82	C, 47.40 H, 2.57 N, 4.64
5.4	N-[4-(5-Chloro-2-hydroxyphenyl)-1-methyl-2-oxo-6-(trifluoro-methyl)-1H-quinolin-3-yl]-4-nitrobenzenesulfonamide	220-235 (dec.)	C ₂₃ H ₁₅ ClF ₃ N ₃ O ₆ S	HRMS* 554.0400 (MH ⁺)	HRMS* 554.0388 (MH ⁺)
5.5	3-Amino-4-(2-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one	244-245	C ₁₆ H ₁₁ F ₃ N ₂ O ₂ •0.25H ₂ O	C, 59.15 H, 3.39 N, 8.63	C, 59.32 H, 3.38 N, 8.56
5.6	4-(2-Methoxyphenyl)-3-phenyl-amino-6-(trifluoromethyl)quinolin-2(1H)-one	241-243	C ₂₃ H ₁₇ F ₃ N ₂ O ₂	C, 67.31 H, 4.18 N, 6.83	C, 67.54 H, 4.19 N, 6.63

<u>Ex. No.</u>	<u>Compound</u>	<u>MP °C</u>	<u>Empirical Formula</u>	<u>Elemental Analysis Calc'd.</u>	<u>Elemental Analysis Found</u>
57	3-Amino-4-(2-hydroxyphenyl)-1-methyl-6-(trifluoromethyl)quinolin-2(1H)-one	215-216	C ₁₇ H ₁₃ F ₃ N ₂ O ₂ •0.25H ₂ O	C, 60.21 H, 3.98 N, 8.26	C, 60.00 H, 3.65 N, 8.01
58	3-Amino-4-(2-methoxy-5-nitro-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one	273-274	C ₁₇ H ₁₂ F ₃ N ₃ O ₄ •0.33 C ₄ H ₈ O ₂	C, 53.88 H, 3.62 N, 10.28	C, 53.49 H, 3.59 N, 9.99
59	3-Amino-4-(4-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one	241-243	C ₁₆ H ₁₁ F ₃ N ₂ O ₂ •0.25H ₂ O	C, 59.17 H, 3.57 N, 8.63	C, 59.29 H, 3.46 N, 8.23
60	3-Amino-4-(5-bromo-2-hydroxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one	246-247	C ₁₆ H ₁₀ BrF ₃ N ₂ O ₂ •0.1 C ₆ H ₁₂	C, 48.89 H, 2.82 N, 6.87	C, 49.25 H, 2.87 N, 6.97

Ex. No.	Compound	MP °C	Empirical Formula	Elemental Analysis Calc'd.	Elemental Analysis Found
6.1	3-Amino-4-(3-chloro-4-methoxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one	248-249	$C_{17}H_{12}ClF_3N_2O_2 \cdot 0.66H_2O$	C, 53.62 H, 3.53 N, 7.36	C, 53.30 H, 3.46 N, 7.41
6.2	3-Amino-4-(3-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one	166-167	$C_{17}H_{13}F_3N_2O_2 \cdot 0.17H_2O$	C, 60.53 H, 3.98 N, 8.31	C, 60.52 H, 3.92 N, 8.11
6.3	3-Amino-4-(3-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one	>360	$C_{16}H_{11}F_3N_2O_2 \cdot 0.2CH_2Cl_2$	C, 57.69 H, 3.41 N, 8.31	C, 57.78 H, 3.27 N, 8.04
6.4	N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-nitrobenzene-sulfonamide	286-287 (dec.)	$C_{22}H_{13}ClF_3N_3O_6S$	HRMS* 540.0244 (MH ⁺)	HRMS* 540.0237 (MH ⁺)

<u>Ex. No.</u>	<u>Compound</u>	<u>MP °C</u>	<u>Empirical Formula</u>	<u>Elemental Calc'd.</u>	<u>Analysis Found</u>
6 5	N-[4-(5-Chloro-2-methoxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-fluorobenzene-sulfonamide	154-156	C ₂₃ H ₁₅ ClF ₄ N ₂ O ₄ S	C, 52.42 H, 2.87 N, 5.32	C, 52.29 H, 2.90 N, 5.19
6 6	N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-fluorobenzene sulfonamide	265-268 (dec.)	C ₂₂ H ₁₃ ClF ₄ N ₂ O ₄ S•0.33 H ₂ O	C, 50.93 H, 2.65 N, 5.40	C, 50.93 H, 2.80 N, 5.18
6 7	N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-y]naphthalene-2-sulfonamide	291-293 (dec.)	C ₂₆ H ₁₆ ClF ₃ N ₂ O ₄ S•0.66 H ₂ O	C, 56.06 H, 3.14 N, 5.03	C, 56.12 H, 3.39 N, 4.77
6 8	3-Amino-4-(5-chloro-2-hydroxy-phenyl)-1-methyl-6-(trifluoro-methyl)quinolin-2(1H)-one	167-168	C ₁₇ H ₁₂ ClF ₃ N ₂ O ₂	C, 58.02 H, 3.25 N, 3.01	C, 57.79 H, 3.30 N, 4.84

Ex. No.	Compound	MP °C	Empirical Formula	Elemental Analysis	
				Calc'd.	Found
6.9	3-Amino-4-(2-hydroxy-5-nitro-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one	215 (dec.)	C ₁₆ H ₁₀ F ₃ N ₃ O ₄ •0.5H ₂ O •0.12C ₆ H ₆	C, 52.38 H, 3.08 N, 10.93	C, 52.36 H, 2.95 N, 10.43
7.0	3-Amino-4-(5-chloro-2-methoxy-phenyl)-1-methyl-6-(trifluoro-methyl)quinolin-2(1H)-one	216-217	C ₁₈ H ₁₄ ClF ₃ N ₂ O ₂ •0.5H ₂ O	C, 55.18 H, 3.86 N, 7.15	C, 55.25 H, 3.54 N, 6.77
7.1	3-Amino-4-(3-chloro-4-hydroxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one	277 (dec.)	C ₁₆ H ₁₀ ClF ₃ N ₂ O ₂ •0.1 CH ₂ Cl ₂	C, 54.18 H, 2.84 N, 7.90	C, 53.80 H, 2.98 N, 7.60

* HRMS = High Resolution Mass Spectrometry

EXAMPLE 724-(5-Chloro-2-methoxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one

5

STEP A. 4-(5-Chloro-2-methoxyphenyl)-3-[[1H-benzotriazol-1-yl)methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one

10 A solution of 3-amino-4-(5-chloro-2-methoxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one(500 mg, 1.36 mmol), benzotriazole methanol (202.9 mg, 1.36 mmol) and absolute ethanol (5 mL) was heated to 60°C overnight (18 hours). The resulting suspension was then cooled and the solids were collected. The solids were then washed with
15 ethanol and air dried affording 4-(5-chloro-2-methoxyphenyl)-3-[[1H-benzotriazol-1-yl)methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one (487 mg, 71.6%).

mp 217-219 °C ¹H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.96(d, 1H, J=8.28 Hz), 7.78(d, 1H, J=8.32 Hz), 7.57(dd, 1H, J=8.68, 1.71 Hz), 7.51(m, 2H), 6.51(m, 1H), 6.06(dd, 1H, J= 14.02, 8.63 Hz), 5.93(dd, 1H, J= 14.04, 8.63 Hz), 3.26(s, 3H). MS m/e: 499 (M-H)⁻.

STEP B. 4-(5-Chloro-2-methoxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one

Sodium borohydride(151.2 mg, 4.0 mmol) was added to a solution of 4-(5-chloro-2-methoxyphenyl)-3-[[1H-benzotriazol-1-yl)methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one (1.0 g, 2.0 mmol)
30 in absolute ethanol and heated to reflux for thirty minutes. The reaction was cooled, acidified with 10% citric acid, extracted with ethyl acetate,

dried over magnesium sulfate, and concentrated. The resulting solid was then chromatographed on silica gel affording 4-(5-chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one (200 mg, 26.1%).

5

mp 238-240 °C. ¹H NMR (DMSO-d₆) δ 12.36(bs, 1H), 7.54(dd, 1H, J=8.85, 2.79 Hz), 7.44(m, 2H), 7.31(d, 1H, J=2.80 Hz), 7.22(d, 1H, J=8.96 Hz), 6.86(m, 1H), 6.06(m, 1H), 3.72(s, 3H), 2.27(d, 3H, J=5.51 Hz). MS m/e: 382 (MH⁺).

10

Anal. calcd. for C₁₈H₁₄N₂O₂F₃Cl: C, 56.48; H, 3.69; N, 7.21.

Found: C, 56.46; H, 3.77; N, 7.21.

15

EXAMPLE 73

4-(5-Chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one

20 Sodium hydride (1.3 g, 27.9 mmol) was added to a solution of 3-amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one (4.7 g, 13.3 mmol) and dry DMF at ambient temperature under nitrogen. Neat chloromethyl methyl ether was added and the reaction was stirred overnight. The reaction was then diluted with

25 saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated. Chromatography on silica gel was used to isolated a mixture of O,N- and O,O- bis methoxymethyl quinolones (3.24g) from remaining starting material. The bis methoxymethyl mixture was dissolved in dry DMF and
30 sodium hydride(375.4 mg, 8 mmol) was added at ambient temperature under nitrogen. Dimethyl sulfate(0.76 ml, 8.0 mmol) was added and the

reaction was stirred for 1 hour. The reaction mixture was then diluted with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated. The crude material was taken up in dry methylene chloride and boron tribromide(1M in methylene chloride, 2.1 eq) was added at ambient temperature under nitrogen. After 6 hours, the reaction mixture was quenched with saturated sodium bicarbonate and extracted with methylene chloride. The organic layer was combined, dried over magnesium sulfate, and concentrated. Chromatography on silica gel afforded 4-(5-chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl)quinolin-2(1H)-one (1.03 g, 21%).

mp 260-262 °C ¹H NMR (DMSO-d₆) δ 12.33(bs, 1H), 9.77(bs, 1H), 7.40(m, 3H), 7.20(m, 1H), 6.98(m, 2H), 6.03(m, 1H), 2.32(m, 3H). MS m/e: 368 (M-H)⁻.

Anal. calcd. for C₁₇H₁₂ClF₃N₂O₂•O•2H₂O: C, 54.84; H, 3.35; N, 7.52.
Found: C, 54.84; H, 3.42; N, 7.24.

20

EXAMPLE 74

4-(5-Chloro-2-methoxyphenyl)-3-[(4-pyridylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

25

mp 205-208 °C ¹H NMR (DMSO-d₆) δ 12.47(bs, 1H), 8.35(d, 2H, J=5.51 Hz), 7.44(m, 3H), 7.03(d, 1H, J=8.95 Hz), 6.95(d, 1H, J=2.70 Hz), 6.81(d, 2H, J=5.75 Hz), 6.75(bs, 1H), 6.62(t, 1H, J=7.48 Hz), 4.01(d, 2H, J=7.43 Hz), 3.46(s, 3H). MS: 459 (M-H)⁻.

30

EXAMPLE 754-(5-Chloro-2-methoxyphenyl)-3-[(phenylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

5

mp 218-220 °C ^1H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.47(m, 3H), 7.23(m, 3H), 7.11(d, 1H, J=8.93 Hz), 7.03(d, 1H, J=2.68 Hz), 6.89(d, 2H, J=6.88 Hz), 6.81(bs, 1H), 6.26(t, 1H, J=7.01 Hz), 3.90(d, 2H, J=7.00 Hz), 3.53(s, 3H). MS m/e: 458 (MH⁺).

10

EXAMPLE 764-(5-Chloro-2-methoxyphenyl)-3-[(2-furanylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

15

mp 198-200 °C ^1H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.52(m, 4H), 7.25(m, 2H), 7.22(m, 2H), 6.88(m, 1H), 6.22(m, 1H), 5.77(t, 2H, J=6.35 Hz), 3.66(m, 5H). MS m/e: 448 (MH⁺).

20

EXAMPLE 774-(5-Chloro-2-methoxyphenyl)-3-[(2-imidazolylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

25

mp 155-159 °C ^1H NMR (DMSO-d₆) δ 12.49(bs, 1H), 7.54(m, 3H), 7.25(m, 2H), 6.89(m, 3H), 6.23(m, 1H), 3.78(t, 2H, J=4.83 Hz), 3.70(s, 3H). MS m/e: 448 (MH⁺).

30

EXAMPLE 784-(5-Chloro-2-methoxyphenyl)-3-[(3-thienylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

5

mp 188-190 °C. ^1H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.50(m, 4H), 7.18(d, 1H, J=8.95 Hz), 7.12(d, 1H, J=2.70 Hz), 6.97(m, 1H), 6.85(bs, 1H), 6.72(dd, 1H, J=4.96, 1.27 Hz), 6.05(t, 1H, J=6.69 Hz), 3.84(d, 2H, J=6.55 Hz), 3.62(s, 3H). MS m/e: 464 (M⁺).

10

EXAMPLE 794-(5-Chloro-2-methoxyphenyl)-3-[(1-methylpyrrolylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one

mp 121-124 °C. ^1H NMR (DMSO-d₆) δ 12.50(bs, 1H), 7.71(m, 1H), 7.56(m, 3H), 7.25(m, 2H), 6.92(bs, 1H), 6.63(m, 1H), 5.84(m, 1H), 5.76(m, 1H), 5.37(t, 1H, J=5.72 Hz), 4.14(m, 1H), 3.72(s, 3H), 3.30(s, 3H). MS m/e: 461 (M-H)⁻.

EXAMPLE 804-(5-Chloro-2-methoxyphenyl)-3-[(4-fluorophenyl)methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one

mp 232-234 °C. ^1H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.47(m, 3H), 7.10(d, 1H, J=8.95 Hz), 7.02(m, 3H), 6.88(m, 2H), 6.78(m, 1H), 6.38(t, 1H, J=7.07 Hz), 3.91(d, 2H, J=6.93 Hz), 3.54(s, 3H). MS m/e: 476 (MH⁺).

EXAMPLE 81

- 5 **4-(5-Chloro-2-methoxyphenyl)-3-[(3-pyridylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one**

mp 160-163 °C ^1H NMR (DMSO-d₆) δ 12.48(bs, 1H), 8.34(dd, 1H, J=4.56, 1.78 Hz), 8.00(d, 1H, J=1.53 Hz), 7.46(m, 1H), 7.24(m, 2H), 7.03(m, 2H), 6.66(bs, 1H), 6.51(t, 1H, J=7.25 Hz), 4.0(m, 2H), 3.50(s, 3H).
10 MS m/e: 459 (MH⁺).

EXAMPLE 82

- 15 **4-(5-Chloro-2-methoxyphenyl)-3-[(2-furanylmethyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one**

mp 193-196 °C ^1H NMR (DMSO-d₆) δ 12.47(bs, 1H), 7.54(m, 2H), 7.47(m, 2H), 7.21(d, 1H, J=8.97 Hz), 7.14(d, 1H, J=2.68 Hz), 6.31(m, 1H), 5.98(d, 1H, J=3.17 Hz), 5.91(t, 1H, J=6.68 Hz), 3.84(m, 2H), 3.65(s, 3H).
20 MS m/e: 448 (MH⁺).

EXAMPLE 83

25

- 4-(5-Chloro-2-methoxyphenyl)-3-[(2-furanyl)-2-propenyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one**

mp 191-193 °C ^1H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.54(m, 5H), 7.27(d, 1H, J=2.69 Hz), 7.21(d, 1H, J=8.95 Hz), 6.86(bs, 1H), 6.42(dd,

- 73 -

1H, J=3.28, 1.84 Hz), 6.31(d, 1H, J= 3.31 Hz), 6.03(m, 2H), 5.74(m, 1H),
3.62(s, 3H). MS m/e: 474 (M-H)⁻.

EXAMPLE 84

5

4-(5-Chloro-2-methoxyphenyl)-3-[[[4-(thiomethyl)phenyl]-
methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one

mp 95-97 °C ¹H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.47(m, 3H),
10 7.10(m, 3H), 7.02(d, 1H, J=2.68 Hz), 6.81(m, 3H), 6.30(t, 1H, J=7.04 Hz),
3.87 (m, 2H), 3.53(s, 3H), 2.41(s, 3H). MS m/e: 504 (M-H)⁻.

EXAMPLE 85

15

4-(5-Chloro-2-methoxyphenyl)-3-[(cyclohexylmethyl)amino]-
6-(trifluoromethyl)quinolin-2(1H)-one

mp 208-210 °C ¹H NMR (DMSO-d₆) δ 12.43(bs, 1H), 7.56(dd, 1H,
20 J=8.84, 2.72 Hz), 7.48(m, 2H), 7.30(d, 1H, J=2.69 Hz), 7.25(d, 1H, J=8.97
Hz), 5.85(t, 1H, J=7.09 Hz), 3.71(s, 3H), 2.38(m, 1H), 1.59(m, 4H),
1.12(m, 6H). MS m/e: 464 (MH⁺).

25

EXAMPLE 86

4-(5-Chloro-2-methoxyphenyl)-3-[[[4-(methoxy)phenyl]-
methyl]amino]-6-(trifluoromethyl)quinolin-2(1H)-one

30 mp 175-178 °C ¹H NMR (DMSO-d₆) δ 12.45(bs, 1H), 7.51(m, 2H),
7.42(d, 1H, J=8.39 Hz), 7.15(d, 1H, J=8.96 Hz), 7.07(d, 1H, J=2.69 Hz),

6.82(m, 5H), 6.09(t, 1H, J=6.70 Hz), 3.80(m, 2H), 3.69(s, 3H), 3.58(s, 3H).
MS m/e: 488 (MH⁺).


Anal. calcd. for C₂₅H₂₀N₂O₂F₂Cl: C, 61.42; H, 4.14; N, 5.39.

5

Found: C, 61.21; H, 4.14; N, 5.39.

What is claimed is:

1. A compound of the formula



5 wherein

R and R¹ each are independently hydrogen or methyl;

R², R³

and R⁴ each are independently hydrogen, halogen, nitro or trifluoromethyl;


10 R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl, trifluoromethylsulfonyl, naphthylsulfonyl, C₁₋₄ alkylcarbonyl, diphenylphosphinyl, cyclohexylmethyl, pyridylmethyl, furanymethyl, furanyl-2-propenyl, imidazolylmethyl, thiienylmethyl, 1-methyl pyrrolylmethyl, unsubstituted or

15 substituted phenyl, phenylmethyl, phenylsulfonyl, phenylcarbonyl, phenylalkylcarbonyl or phenylglyoxyloyl wherein said phenyl substituent is selected from the group consisting of one or two fluoro, hydroxy, trifluoromethyl, amino, methoxy, methylthio and nitro; and

20 R⁶ is hydrogen, bromo, chloro or nitro;

or a nontoxic pharmaceutically acceptable salt thereof.

2. A compound of claim 1 having the formula



wherein

R and R¹ each are independently hydrogen or methyl;

5 R², R³

and R⁴ each are independently hydrogen, chloro, nitro or trifluoromethyl;

R⁵ is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylsulfonyl,

trifluoromethylsulfonyl, cyclohexylmethyl, pyridylmethyl,


10 furanylmethyl, furanyl-2-propenyl, imidazolylmethyl, thienylmethyl, 1-methyl pyrrolylmethyl, unsubstituted or substituted phenyl, phenylmethyl, phenylcarbonyl or phenylsulfonyl wherein said phenyl substituent is selected from one or two fluoro, hydroxy, trifluoromethyl, methoxy,

15 methylthio and nitro; and

R⁶ is chloro;

or a nontoxic pharmaceutically acceptable salt thereof.

3. A compound of claim 2 having the formula



20

wherein

R is hydrogen;

R¹ is hydrogen or methyl;
R², R³
and R⁴ each are independently chloro, nitro or trifluoromethyl;
5 R⁵ is hydrogen, methyl, C₁₋₄ alkylsulfonyl, trifluoromethylsulfonyl, unsubstituted or substituted phenyl, phenylmethyl, phenylmethyl, phenylcarbonyl or phenylsulfonyl wherein said phenyl substituent is selected from one or two fluoro, hydroxy, trifluoromethyl, methoxy, methylthio and nitro; and
10 R⁶ is chloro;
or a nontoxic pharmaceutically acceptable salt thereof.

4. A compound of claim 1 selected from the group consisting of:

15 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl) quinolin-2(1H)-one;

3-Amino-4-(5-chloro-2-hydroxyphenyl)-7-(trifluoromethyl) quinolin-2(1H)-one;

20 4-(5-Chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl) quinolin-2(1H)-one;

25 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;

N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-7-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;

30 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]methanesulfonamide;

- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl] phenylsulfonamide;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-dichloroquinolin-2(1H)-one;
5 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]aminocarboxylic acid, phenylmethyl ester;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-nitroquinolin-2(1H)-one;
10 3-Amino-4-(5-chloro-2-hydroxyphenyl)-7-nitroquinolin-2(1H)-one;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]diphenylphosphinamid;
15 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,6-dichloroquinolin-2(1H)-one;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-hydroxybenzenesulfonamide;
20 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl) quinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-bis (trifluoromethyl)quinolin-2(1H)-one;
25 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloroquinolin-2(1H)-one;

- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-7-(trifluoromethyl) quinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-chloro-5-(trifluoromethyl) 5 quinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-iodoquinolin-2(1H)-one;
- 4-(5-Chloro-2-hydroxyphenyl)-3-[(4-hydroxyphenyl)amino]-6- 10 (trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-hydroxyphenyl)-3-[(3,5-dihydroxyphenyl)-amino]-6- (trifluoromethyl)quinolin-2(1H)-one;
- 15 4-(5-Chloro-2-methoxyphenyl)-3-[(3,5-dihydroxyphenyl)- amino]-6- (trifluoromethyl)quinolin-2(1H)-one;
- 4-(5-Chloro-2-methoxyphenyl)-3-[(4-hydroxyphenyl)amino]-6- 20 (trifluoromethyl)quinolin-2(1H)-one;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin- 3-yl]-4-(trifluoromethyl) benzenesulfonamide;
- N-[4-(5-Chloro-2-hydroxyphenyl)-1-methyl-2-oxo-6-(trifluoro-methyl)-1H- 25 quinolin-3-yl]-4-nitrobenzenesulfonamide;
- 3-Amino-4-(4-hydroxyphenyl)-6-(trifluoromethyl)quinolin-2(1H)-one;
- 3-Amino-4-(5-bromo-2-hydroxy-phenyl)-6-(trifluoromethyl) quinolin- 30 2(1H)-one;

- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-nitrobenzene-sulfonamide;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-fluorobenzene sulfonamide;
- 3-Amino-4-(5-chloro-2-hydroxy-phenyl)-1-methyl-6-(trifluoro-methyl) quinolin-2(1H)-one;
- 10 3-Amino-4-(2-hydroxy-5-nitro-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one; and
- 3-Amino-4-(3-chloro-4-hydroxy-phenyl)-6-(trifluoromethyl) quinolin-2(1H)-one.
- 15 5. A compound of claim 4 selected from the group consisting of:
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl) quinolin-2(1H)-one;
- 20 4-(5-Chloro-2-hydroxyphenyl)-3-(methylamino)-6-(trifluoromethyl) quinolin-2(1H)-one;
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;
- 25 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-7-(trifluoromethyl)-1H-quinolin-3-yl]trifluoromethanesulfonamide;
- 30 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl] phenylsulfonamide;

- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,6-dichloroquinolin-2(1H)-one;
- 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5-(trifluoromethyl) quinolin-2(1H)-one;
- 5 3-Amino-4-(5-chloro-2-hydroxyphenyl)-5,7-bis (trifluoromethyl)quinolin-2(1H)-one;
- 10 4-(5-Chloro-2-hydroxyphenyl)-3-[(4-hydroxyphenyl)amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 15 4-(5-Chloro-2-hydroxyphenyl)-3-[(3,5-dihydroxyphenyl)-amino]-6-(trifluoromethyl)quinolin-2(1H)-one;
- 20 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-(trifluoromethyl) benzenesulfonamide;
- 25 N-[4-(5-Chloro-2-hydroxyphenyl)-1-methyl-2-oxo-6-(trifluoro-methyl)-1H-quinolin-3-yl]-4-nitrobenzenesulfonamide;
- 30 N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-nitrobenzene-sulfonamide; and
- N-[4-(5-Chloro-2-hydroxyphenyl)-2-oxo-6-(trifluoromethyl)-1H-quinolin-3-yl]-4-fluorobenzene sulfonamide.
- 30 6. A pharmaceutical composition for the treatment of disorders responsive to openers of the large conductance calcium-activated potassium channels comprising a therapeutically effective amount of a

compound as defined in claim 1 in association with a pharmaceutically acceptable carrier or diluent.

7. A method for the treatment of disorders responsive to opening of
5 the large conductance calcium-activated potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound as defined in claim 1.
- 10 8. A method of claim 7 wherein said disorder is ischemia, stroke, convulsions, epilepsy, asthma, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, male erectile dysfunction and urinary incontinence.
- 15 9. The method of claim 8 wherein the disorder is stroke.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US98/17508

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/47; C07D 215/38, 215/227
US CL :514/312; 546/157

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/312; 546/157

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,202,661 A (BRUST et al.) 24 August 1965, column 1; column 7, example 3.	1-4, 6
A	US 5,565,483 A (HEWAWASAM et al.) 15 October 1996, see entire document, especially column 2.	1-9
A	US 5,223,513 A (MEGURO et al.) 29 June 1993, columns 1-3.	1-9

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

03 NOVEMBER 1998

Date of mailing of the international search report

17 DEC 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

EVELYN HUANG

Telephone No. (703) 308-1235